Correlative study of the clinical, pathological and molecular biological features of creutzfeldt-jakob disease by De Silva, Rajith Nilantha
THE UNIVERSITY of EDINBURGH
£> i n
Title A correlative study of the clinical, pathological and
molecular biological features of creutzfeldt-jakob disease
Author De Silva, R. N.
Qualification MD
Year 1998
Thesis scanned from best copy available: may
contain faint or blurred text, and/or cropped or
missing pages.
Digitisation notes:
• P.49 missing from original numeration.
Scanned as part of the PhD Thesis Digitisation project
http://libraryblogs.is.ed.ac.uk/phddigitisation
A CORRELATIVE STUDY OF THE CLINICAL, PATHOLOGICAL AND
MOLECULAR BIOLOGICAL FEATURES OF CREUTZFELDT-JAKOB
DISEASE
Rajith Nilantha de Silva
Degree of Doctor of Medicine
The University of Edinburgh
1998
To IB, RGW and CPW, my mentors in Neurology
ACKNOWLEDGEMENTS
This work would not have been possible without the guidance and assistance of
a large number of individuals, only some of whom are mentioned here by name.
This is particularly true in relation to the relatives of the patients studied here.
Their eagerness to assist me, in frequently tragic circumstances, was
astonishing, not to mention their acts of kindness and hospitality. I hope that this
research is of some small consolation. Also not mentioned individually are
colleagues in Neurology, Neurophysiology and Neuropathology all over the UK,
who referred cases and gave unstintingly of their time when I was in their units
collecting data.
The following were my partners in crime: Bob Will, Tom Esmonde, Martin
Zeidler, James Ironside, Jeanne Bell, Ken Sutherland, Ian Goodbrand, Jan
MacKenzie, Sandie Honeyman, Linda McCardle, Caroline Barrie, Dave
Nicholson, Otto Windl, Maureen Dempster, Peter Estibeiro and Jim Slattery.
DECLAMTICN
I, Rajith N. de Silva, hereby confirm that this thesis has been composed by myself. The work
undertaken was part of a research effort by several individuals, but my contribution to the data




PRNP Human prion protein gene
ORF Open reading frame (of gene)
ATD Dementia of Alzheimer type
PrP Prion protein
BSE Bovine spongiform encephalopathy
HGH Human growth hormone
HGnH Human gonadotrophin
FFI Fatal familial insomnia
EEG Electroencephalogram
GSS Gerstmann-Straussler syndrome
NIH National Institutes of Health
CT Computerised tomography
CSF Cerebrospinal fluid
MRI Magnetic resonance imaging
LMN Lower motor neurone
PrPc Protease-sensitive PrP




vCJD New variant CJD
PCR Polymerase chain reaction
SSCP Single-strand conformational
polymorphism
OPCS Office of population, census and
statistics
ABSTRACT
A systematic study of all patients with pathologically or electrophysiological^
confirmed Creutzfeldt-Jakob disease (CJD) referred to the U.K. national
surveillance unit between May, 1990 and April, 1994 has been undertaken. The
numbers of sporadic, familial and iatrogenic cases were 144, 14 and 12
respectively. Sporadic CJD cases had a median age at presentation of 65 years,
and a median disease duration of 4 months. Familial cases (associated with
mutations of the open reading frame of the prion protein gene, PRNP ORF)
presented 10 years earlier and had disease durations which were twice as long.
Clinical characteristics at different stages of illness were identified. At
presentation, around 40% of sporadic cases had some aspect of cognitive
impairment in isolation, 30% had cerebellar dysfunction in isolation, 10% had a
combination of cognitive and cerebellar dysfunction, and 10% had occipital
blindness. Alternative modes of presentation were unusual (<10%). In most of
the 30% of sporadic cases that had cerebellar dysfunction as their presenting
feature, other neurological abnormalities quickly supervened; the form of CJD
characterised by pure progressive cerebellar ataxia was extremely rare (<4%).
The clinical characteristics of the sporadic and the grouped familial cases did
not differ. Characteristic electroencephalographic findings were present in 35%
of pathologically confirmed cases. Familial cases were more likely to have a
family history of (non-specific) neurodegeneration. Iatrogenic cases in whom the
agent was inoculated outside the central nervous system were shown to have a
different clinical profile early in the illness from sporadic cases.
The clinical characteristics of the sporadic and familial cases were compared at
different stages of illness with those of a group of patients with suspected CJD
whose neuropathological examinations had revealed an alternative
neurodegenerative process (non-CJD). The relative sensitivities and specificities
of the standardised criteria used in the clinical evaluation of suspect CJD cases
were high, with the exception of "neurogenic muscle wasting". The non-CJD
group had a disease duration that was four times as long as the sporadic CJD
cases. In this group, Alzheimer-type dementia was the commonest diagnosis
with a large proportion having myoclonus.
The correlation of clinical features with spongiform change distribution in
different parts of the brain was in general poor. Various explanations for this
discrepancy have been offered. Around 15% of sporadic CJD cases were found
to have unicentric anti-PrP positive amyloid plaques. These cases were more
likely to be associated with alleles encoding valine at position 129 of the PRNP
ORF.
The vast majority of sporadic CJD cases were methionine homozygous at codon
129 of the PRNP ORF. The ages of onset and disease durations between
patients who were homozygous and heterozygous at this site of common
polymorphism did not vary. Patients who bore alleles encoding valine at this site
(as well as demonstrating amyloid plaques) were more likely to present with
cerebellar ataxia and were unlikely to have typical electroencephalographs.
Despite the incurable and devastating nature of CJD, relatives were keen to
know the results of PRNP genome analysis in patients.
A comprehensive classification of human spongiform encephalopathy as
understood in the early 1990s has been presented. This constitutes a
background against which probable novel forms of human spongiform
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Creutzfeldt-Jakob disease (CJD) is a rare and invariably fatal
neurodegenerative disease, characterised by spongiform change of the
central nervous system and transmissibility. It is one of a group of disorders
affecting a variety of mammalian species (Table 1). In humans, the illnesses
traditionally associated with spongiform encephalopathy are sporadic CJD
(with no known causation), familial CJD (attributable to inherited factors),
iatrogenic CJD (due to medical "misadventure") and kuru. Despite their rarity
(the annual incidence of sporadic CJD worldwide is 0.5 to 1.0 cases/million
population/year),1 these disorders have attracted an extraordinary amount of
lay interest. The epidemic of Bovine Spongiform Encephalopthy (BSE)2 has
fuelled speculation on the impact of this animal spongiform encephalopathy
on humans. Amongst scientists, interest in the spongiform encephalopathies
arises due to two reasons. Firstly, these disorders straddle the entire
spectrum of mechanisms by which human disease is traditionally thought to
be caused. On the one hand CJD can arise from purely genetic factors and
on the other the illness is apparently purely environmentally acquired (for
example, in recipients of "infected" pituitary-derived human growth hormone
[HGH]3). Secondly, the nature of the putative "agent" of infectivity has
remained remarkably difficult to characterise, being apparently devoid of
nuclear material and being denatured by proteolytic agents only.4
The prion hypothesis has emerged as a credible explanation for some of
these unusual features. In this, it is argued that the vector of infectivity is a
conformational isoform of a naturally occurring protein (prion protein [PrP]),
with a capacity to convert normal PrP to its abnormal isoform
autocatalytically. In humans, the gene encoding PrP (PRNP) is located on the
short arm of chromosome 20. Familial forms of CJD have been associated
with mutations in PRNP, and a site of common polymorphism appears to
render increased susceptibility to iatrogenic, sporadic and possibly new
l
variant CJD (vide infra). The normal role of PrP has not been fully elucidated.
In early PrP-null transgenic mouse models, no abnormalities were noted,145
but later experiments have revealed abnormal sleep patterns,147 altered
electrophysiological characteristics146 and possibly accelerated cerebellar
Purkinje cell loss.211
The clinical manifestations of CJD are protean, and there are no consistently
reliable diagnostic tests. These factors contribute to its diagnostic difficulty.
Within the diverse clinical signs, however, patterns are recognised, and forms
of the illness characterised by occipital blindness5 and progressive cerebellar
ataxia6 are recognised. The improved diagnosis of familial forms of CJD,
frequently utilising PRNP genome analysis, has broadened the spectrum of
clinical features associated with CJD to include atypical characteristics, such
as dysautonomia.7 Furthermore, in iatrogenic CJD and especially where the
agent of infectivity is introduced outside the central nervous system, the
clinical phenotype is remarkably homogeneous.8
CJD is associated with distinct neuropathological features. In addition to
microscopic spongiform change, there is astrocytosis and neuronal cell loss.9
In a proportion of cases, there are abnormal amyloid protein aggregates-
termed plaques. Immunocytochemistry with anti-PrP antibodies has revealed
positive staining of these lesions, and also within and around areas of
confluent spongiosis.10
The current study is an exploration of the clinical phenotypes associated with
CJD, based on cases referred to the UK national CJD surveillance unit up to
1994. The unit was set up in 1990, following the recommendation of the
Southwood committee, which reported to Parliament on the likely impact of
BSE.12 In addition to collecting epidemiological data on a variety of putative
2
"risk factors", detailed clinical profiles of patients referred to the unit are
available. As the route of inoculation in iatrogenic CJD may be crucial in
determining the clinical presentation, human exposure and susceptibility to
BSE might result in an altered clinical phenotype. The detailed clinical
profiles are used to describe the frequency of common and unusual clinical
signs in cases during the period of study. These profiles are compared with
those of a group of "control" patients, also referred to the unit with suspected
CJD, but whose neuropathological examination did not confirm CJD. In those
cases with neuropathological data, the clinical phenotypes are correlated with
pathological appearances (in particular spongiform change). Clinico-
pathological correlation is also attempted in cases with amyloid plaques. Data
on PRNP genotype is available in a proportion of cases, and in these
correlation with clinical (and, where available, pathological) features is
performed. Ethical considerations in relation to PRNP genome analysis are
also explored.
1.1 Early clinical descriptions
H.G. Creutzfeldt (Figure 1) is credited with the first description of the
disorder, although by current diagnostic criteria his case is atypical.13 The
patient was twenty-three years at presentation and there was a questionable
family history of mental subnormality. In adolescence the patient was noted to
be immature and had behavioural abnormalities. A year prior to presentation,
she was treated for a skin rash and at that time spastic paraparesis was
recorded. The latter improved thereafter, but there were features of
psychiatric disturbance, cerebellar ataxia and possibly dystonia at the time of
presentation. During her terminal hospitalisation, her behaviour continued to
be disturbed, she exhibited a variety of cognitive deficits, pyramidal and
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cerebellar signs, and probably had myoclonus. She died in status epilepticus,
two months after presentation. The neuropathological findings were those of
"...a noninflammatory focal disintegration at the neural tissue of the cerebral
cortex with neuronophagy and reparative glial proliferation..."13 A year later,
in 1921, A. Jakob (Figure 2) described four cases, at least one of whom had
clinical features suggestive of the entity we recognise as CJD now (Table
2).14 A further case which Jakob considered similar was described in 1923.15
Masters and Gajdusek have reviewed the pathology of Jakob's five cases,
and conclude that only cases 3 and 5 have got spongiform encephalopathy.16
They suggest that case 1 had motor neurone disease, and that cases 2 and 4
had toxic or metabolic encephalopathies. Kirschbaum had come to a similar
conclusion (clinically) regarding case 4.17
Over the next forty years there was considerable confusion over
nomenclature, with at least twelve synonyms being applied to this disorder.18
Of these, three descriptions are worthy of further mention.
1.1.1 "Subacute vascular encephalopathy"
In 1954 and 1960, Nevin and colleagues in two elegant series described a
total of ten patients, all of whom succumbed to a neurodegenerative process
of subacute onset and rapid progression.19,20 They drew attention to the
combination of pyramidal and cerebellar disturbance, the presence of
involuntary movements especially myoclonus, the frequent occurence of
visual failure, the spectrum of speech disturbances (dysphasia, dyspraxia
and mutism), the recurrence of primitive reflexes, and the rigidity ("Passive
movements were resisted..."). The association of the disorder with
characteristic electroencephalogram (EEG) appearances was indicated,
although it was also stressed that the EEG abnormalities were not specific20
Finally, the authors gave detailed descriptions of the neuropathological
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appearances, and on account of the spongiform change concluded that the
aetiology of the disorder was microvascular dysfunction. Despite the
erroneous attribution of causation, these descriptions remain the most
comprehensive accounts of the clinical course of CJD.
1.1.2 Heidenhain's syndrome
In 1929 Heidenhain reported three cases of rapidly progressive dementia,
two of whom had had blindness during the terminal phase.21 The
neuropathological features were those of CJD, but in the patients with
blindness the degree of spongiform change was most pronounced in the
occipital cortices (including the calcarine regions). In 1954 Meyer and
colleagues reviewed Heidenhain's cases and reported a further case.5
Meyer's case was a man aged 38 who died six months after the onset of
progressive dementia accompanied by visual failure. On examination, he was
severely demented, appeared to have a right homonymous hemianopia, had
exaggerated limb reflexes on the left and was ataxic. On histological
examination after necropsy, diffuse spongiform change affecting all cortical
regions was confirmed, but once again the changes were most pronounced in
the occipital lobes. In the calcarine regions the appearances were those of
"status spongiosus" (similar to Heidenhain's second case). In conclusion,
Meyer et al felt that these cases represented a variant form of CJD
characterised by rapidly progressive dementia and cortical blindness, with
less involvement of the pyramidal and extra-pyramidal systems. It is of note
that all three patients exhibited cerebellar signs in addition.
1.1.3 Ataxic CJD
In 1965 Brownell and Oppenheimer described four patients with
pathologically confirmed CJD.6 All four had presented with cerebellar ataxia,
as had six cases they reviewed from the literature. The pathological
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appearances were those of CJD, with neuronal cell loss and astrocytosis
being particularly noted in the cerebellum. The authors themselves drew
attention to their fourth case, which had a slightly unusual course. A 60 year-
old woman was seen with a six month history of difficulty walking. The key
examination findings were gross limb tremor and gait ataxia. At initial
assessment, she was "vague and forgetful" but fully orientated. Within the
space of a month she had become disorientated and demented. By then she
was unable to stand or walk without support. Terminally, she had feeding
difficulties and was doubly incontinent. At the time of death, the suspected
diagnosis was (idiopathic) cerebellar degeneration (lumbar puncture and air
encephalography had been normal). The total duration of illness had been 8
months.
As indicated in their discussion, this case (of CJD) was unusual in having a
course that was for the most part dominated by cerebellar ataxia, with
dementia being a late feature. The pathological changes in the cortex of this
case were slight, but the authors felt that there was no reason why "...in this
variable condition, varieties should not occur in which the cerebral cortex
remains more or less intact."
1.2 Gerstmann-Straussler syndrome (GSS)
In 1928 Gerstmann described an unusual inherited cerebellar disorder. A 25
year-old woman developed ataxia, dysarthria and personality change, and on
review a year later had more pronounced ataxia and dementia.22 Over the
next five years (leading to death) the patient exhibited "pseudobulbar
disturbance of swallowing", nystagmus (lateral and upgaze), limitation of
upgaze, hypotonia, intention tremor, diminished reflexes and bilaterally
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upgoing plantar responses. In a subsequent publication,23 the detailed clinical
and pathological features of this case along with the family history (there
were seven other affected members) were described. The pathological
appearances were those of neuronal loss in most areas of the cerebellum
and in the dentate nuclei, corticospinal and cerebellar peduncle fibre loss,
cerebral cortical gliosis, and argyrophilic plaques throughout the cerebellum,
cerebrum and brainstem. Spongiform change was present but not striking. In
their seminal publication in 1981, Masters et al. reviewed Gerstmann's case
along with nine other cases in the literature sharing similar clinical and
pathological features.24 Seven further cases with identical phenotypes
referred to the authors' laboratory for transmission experiments were included
in the paper. In three of the latter group, a spongiform encephalopathy had
occured after inoculation of brain tissue into nonhuman primates. In the group
as a whole, the mean age at death was 48 years (range 29 to 62) and the
mean duration of disease was 59 months (range 13 to 132). The key clinical
features were characterised as cerebellar incoordination, pyramidal signs
and dementia. Myoclonus was not a constant finding. The slow evolution of
the illness was felt to be the main differentiating feature of this group of
patients, from patients with CJD.
In 1990 "linkage" of a missense variant at codon 102 of PRNP was
demonstrated in GSS,25 and in 1991 the same mutation was identified in
Gerstmann's original family.26
1.3 Kuru
The epidemic of kuru which predominantly affected the Fore-speaking people
of the highlands of Papua New Guinea, was recognised as a progressive and
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eventually fatal neurodegenerative process predominantly affecting the
cerebellum.27,28 In 1979 R.W. Hornabrook presented a comprehensive review
of the clinical features of this illness, based on his experience with 434
cases.29 The most salient observation was the remarkable uniformity of
clinical features in affected patients. ("A resemblance which could not be
closer were they coined from the same mint."29) During a prodrome of twelve
months or more, affected patients would show transient unsteadiness. At this
time minor changes in personality and mood (mild euphoria, tendency
towards fatuousness and lack of insight) may have been present. The clinical
illness itself was characterised by progressively worsening ataxia and the
inability to maintain balance. In the last stages patients were unable to sit or
perform any activity, were grossly dysarthric and were unable to swallow.
Death would ensue 12-18 months after the onset of the clinical illness.
Dementia was probably present at the terminal stage of disease. Signs of
extra-pyramidal disease, rigidity, myoclonus and seizures were absent. In
children, the clinical illness was more variable and of shorter duration.
Brainstem and bulbar dysfunction appeared to occur more commonly than in
adults.
W. Hadlow's prescient comments on the histopathological similarities
between brains affected by scrapie and kuru,30 led to the successful
transmission of kuru by intracerebral inoculation of kuru brain or mixed
visceral tissues into chimpanzees and monkeys.31 This supported the theory
that endocannibalistic practices (not just consumption, but also contamination
and subsequent inoculation via mucous membranes, skin and eyes) were
responsible for this illness. Furthermore, there has been a dramatic fall in the
number of kuru cases born after the cessation of these practices in around
1956.32
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In the foregoing, early descriptions of CJD have been reviewed. Variant
sporadic forms such as those presenting with cortical blindness and illnesses
dominated by cerebellar incoordination were recognised early in the history
of this disorder. Transmission of CJD to non-human primates by intracerebral
inoculation was achieved in 1968, establishing the commonest human
spongiform encephalopathy as a transmissible disorder (albeit under
experimental conditions).33 Rare types of human spongiform encephalopthy
related to familial factors and endocannibalism have also been reviewed.
Over the 1970s several large epidemiological studies were performed to
investigate the possibility that sporadic CJD arose from case-to-case
transmission. No evidence for this hypothesis emerged,34"37 but in the course
of these investigations a large amount of data on the clinical features of CJD
was collected.
2.1 Observations from epidemiological studies
All of the studies used diagnostic criteria modified from those put forward by
Masters et al.38 On the whole neuropathologically confirmed cases were
defined as "definite", and those with characteristic electroencephalograph^
appearances and appropriate clinical features were designated "probable".
The analysis of electroencephalographic appearances is entirely subjective,
and criteria such as "periodic synchronous discharges"35 and "pseudoperiodic
slow-wave spikes"39 may not have been used consistently in different series.
The clinical analysis presented by P. Brown based on his work in France40 is
notable for including neuropathologically confirmed cases of CJD only, and
his recent study from the National Institutes of Health (NIH) looked at the
clinical characteristics of 300 cases all of whom had been successfully
transmitted to nonhuman primates.41 Will and Matthews excluded four cases
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of "possible" CJD (no typical EEG available) but included six cases of
"possible" CJD of amyotrophic form (vide infra) in the analysis of clinical
features in 158 cases.42
2.1.1 Familial versus sporadic
Masters' own series suggested that the proportion of cases that were familial
(due to inherited factors) was 15%.43 However, this value could be criticised
as an over-estimate as cases in which a family member had already been
investigated were more likely to be referred to this group. Indeed, the large
scale epidemiological studies in England & Wales and France estimated the
prevalence of familial CJD to be around 6%.44,36 Interestingly, Galvez et al
estimated the proportion of cases that were familial in their series from Chile
to be 47%, a figure almost certainly related to the high prevalence of the
mutation at codon 200 of PRNP in this population.45 The estimate for familial
CJD was generally accepted as between 5 and 10%, although with hindsight
an accurate estimate could only be provided by the systematic screening of
unselected cases of CJD for mutations of PRNP.
2.1.2 Age of onset, and disease duration
In Brown's 1986 study40 the mean age of onset was 61.5 years (range 19 to
83), and the mean disease duration was 7.6 months (median 4.0). In his
larger series of 1994,41 in a subgroup of sporadic cases (n=234) the mean
age of onset was 60 years (range 16 to 82, median 60) and the median
disease duration was 4.5 months (range 1 to 130, mean 8). In the latter study,
in the familial subgroup (n=40, with PRNP mutations demonstrated in 35) a
younger age of onset and a longer duration of disease were noted. The
longer durations of disease in younger patients noted in the earlier study may
have partly been due to the same phenomenon.
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Will and Matthews divided their patients into three groups: subacute,
intermediate and amyotrophic.42 The classification was based on the clinical
courses of their patients, and while there was no difference in age at death of
patients in the three groups, patients with intermediate and amyotrophic
forms of CJD had longer courses. Intermediate cases were difficult to
diagnose in life, as they masqueraded frequently as some of the commoner
neurodegenerative diseases (such as Alzheimer's disease (ATD)).
Numerically, however, these cases were small in number (12 out of 158
cases in their series).
2.1.3 Clinical courses
Cathala and Baron refer to a prodromal clinical stage in a third of patients,
consisting of non-specific features such as fatigue, sleeping difficulties,
weight loss, headaches, malaise and "sensations".46 However, Knight argues
persuasively that these symptoms are "...common, non-specific, and often
noted later, when developments have lent them retrospective and possibly
spurious significance."47
Symptoms and signs at the start of and during the course of CJD in the larger
series are summarised in Table 3. The data available from Will and Matthews
pertains to 137 definite and probable, subacute cases. With respect to the
debut of their illnesses, 30-40% of patients had cognitive impairment alone,
30-40% had neurological disease in isolation and 20-30% had mixed
features. As can be seen in Table 3, there is some variation in the reported
frequency of features but this is probably due to differences in the
classification of symptoms and signs in the various studies as well as chance
variation of clinical features amongst the patients studied. Several general
conclusions can nevertheless be drawn. Firstly, dementia was always present
during the course of illness in these mostly sporadic CJD cases. Secondly,
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myoclonus, which was rarely seen at the onset, was frequently noted during
the course of disease. Thirdly, features of cerebellar, visual, pyramidal and
extra-pyramidal dysfunction were noted regularly but were not universal.
Finally, features of lower motor neurone dysfunction and convulsions were
rare presenting features, and were unusual even during the course of illness.
2.1.4 Investigation results
Routine biochemical and haematological investigations were normal in these
series, with the exception of liver function tests (32 abnormal out of 80 cases
for whom results were available in Will and Matthews' study42). Computerised
tomography (CT) was usually normal but occasionally revealed atrophy,
especially in cases with more protracted illnesses. Examination of
cerebrospinal fluid (CSF) was sometimes abnormal. Extrapolating from Will
and Matthews' data, the CSF protein content was greater than 0.4 g/l in 45%
of cases where it was examined.
Of the investigations performed, abnormalities in the EEG were the most
useful in establishing the diagnosis. Given the inclusion of characteristic EEG
appearances in the diagnostic criteria of these epidemiological studies, there
would have been a tendency for over-ascertainment of this feature. Also, as
already indicated, given the subjective interpretation of EEGs there may have
been considerable variation in the types of abnormalities included. Will and
Matthews found typical EEG findings in 84% of subacute cases, where an
EEG had been performed. In their intermediate group (with atypical clinical
courses) the EEG was typical in only 2/9 cases where it was performed.
Brown et al report "periodic" EEG appearances in 60-80% of patients, and
"triphasic 1 cycle/second" in 48-56%.
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Systematic data on brain biopsy of suspected cases is available in Brown's
NIH study. In 52 out of 55 autopsy-verified cases, the brain biopsy had
revealed spongiform change. Against this high rate of diagnosis has to be
considered the attendant risks of accidental transmission of CJD to other
patients and staff.48,49 The same study pointed out the utility of examining
CSF by two-dimensional electrophoresis for a pair of novel proteins,50,51 now
identified as the 14-3-3 brain protein and detectable by immunoassay.52 None
of the studies give data on Magnetic Resonance Imaging (MRI) in cases of
CJD.
In summary, these large epidemiological studies gave fairly consistent
profiles of CJD, with respect to the proportion of cases that were familial, the
patients' ages of disease onset and the durations of their disease, the clinical
features of the illness, and the results of investigations. The major advances
in the study of CJD in the 1980s arose from the field of molecular biology, in
particular the experiments designed to test the "prion" theory of disease
causation. Before embarking on a review of the theory and an appraisal of
the key experiments, three unusual variants of CJD are discussed: those with
long disease durations, and the so-called "amyotrophic" and
"panencephalopathic" forms of CJD.
2.2 CJD of long duration
As noted, the duration of disease in sporadic cases of CJD is usually 4.0 to
4.5 months. In familial cases the illness is of longer duration, which may
account partly for the longer course noted in younger patients (who are also
more likely to have an inherited form of CJD). Will and Matthews give
accounts of the clinical courses of their "intermediate" cases (6% of their
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series), and three distinct types of disease progression are noted: a form of
CJD characterised by slow but inexorable progression, a form in which a slow
neurodegenerative process is followed by a rapid terminal phase, and (most
rare of all) a rapid early course followed by a protracted terminal state in
which there is little further decline.42 As a group, these patients had a mean
disease duration of 33.4 months. It is of note that 2 (of the 12) cases had
family histories of neurodegenerative processes.
In a further seminal publication, P. Brown and colleagues summarised their
experience with cases of CJD of disease durations longer than two years.53 At
the time of this study, the cases represented 9% of those with
histopathologically verified CJD. They were characterised by a higher
likelihood of having familial disease, a younger age of onset, and lower
frequencies of myoclonus and periodic EEG appearances during the clinical
illness. The difficulty of differentiating these cases from patients with other
chronic dementing processes (particularly ATD) was stressed. Intriguingly, in
transmission studies primate inoculations were less successful in these
cases, than in those with shorter disease durations. (The incubation periods
and disease durations in the inoculated animals did not differ from those
inoculated with tissue from short duration cases.) In Brown's later NIH series,
a lower rate of successful transmission was achieved with familial cases,41
and the lower rate of successful transmission in their earlier series is
probably due to the presence of cases of inherited CJD within the group of
patients with long duration disease. This observation would also account for
the unusual epidemiological characteristics of this group. Nevertheless, in the
NIH series, there were still 9 (4%) sporadic patients with illnesses longer than
two years, with the longest duration of disease being 4.5 years. Of the
previously identified subtypes, there were three patients each in the slow,
slow-fast and fast-slow groups.
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2.3 Amyotrophic CJD
As indicated in the epidemiological studies, signs of lower motor neurone
dysfunction are encountered in CJD, but these are uncommon and do not
occur in the absence of more widespread cortical and cerebellar disease.
Furthermore, their presence at the start of the clinical illness is extremely
unusual. Salazar et al reviewed this subject in 1983, and came to the
conclusion that "...the great majority of cases involving syndromes of
dementia and early onset of LMN (lower motor neurone) signs are clinically
and pathologically distinct from the typical cases of CJD and do not represent
transmissible disease caused by unconventional viruses as presently
understood."54 They based their conclusion on the negative transmission
studies they performed, and also on the atypical neuropathological
appearances. The most consistent feature in the latter examinations was
atrophy (with neuronal loss and gliosis) in the frontotemporal cortex. It is now
recognised that frontotemporal atrophy is the pathological hallmark of the
dementia that sometimes accompanies motor neurone disease.55,56
Confusingly, there may be secondary spongiform change in these regions,9
which may account for the previous inclusion of this disorder in the human
spongiform encephalopathies. It is the present author's view that
"amyotrophic CJD" is a misnomer, and in the majority of cases represents
motor neurone disease with dementia. In Salazar et als series only 2 out of
33 cases with dementia and early lower motor neurone signs transmitted:
both had chronic peripheral neuropathies and also typical CJD brain
histology. They probably represented cases of CJD that had developed by
chance in individuals with chronic neuropathies.
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2.4 Panencephalopathic CJD
This pathological variant of CJD is described almost exclusively in the
Japanese literature,46 and is characterised by extensive white matter
degeneration in cases of CJD. There is probably no difference in the clinical
presentations of these patients, although reports have implicated a longer
duration of disease, and evidence of cortical atrophy and white matter
disease (on CT and MRI) in these cases.57,58 A further report has implicated
the coexistence of amyloid plaques.59 The negligible experience of this entity
in Western series makes it difficult to gauge its importance in CJD. It may
represent a unique interaction of a strain (?) of CJD with the unusual host
genotype of the Japanese population.60
3.1 The "prion" hypothesis
The suggestion that the agent of infectivity of scrapie may be devoid of
nucleic acid was first made by Tikvah Alper and colleagues as far back as
1967.212 They based this on the observation that scrapie infectivity was
resistant to irradiation, including ultraviolet at 254 nm. Stanley Prusiner
resurrected the concept in the early 1980s, and argued that the agent was
composed mainly, if not wholly, of protein; hence the term prion (a
proteinaceous /'nfectious particle).4 Prusiner's suggestion was met with
considerable scepticism, but over the ensuing 20 years he performed a series
of experiments to support his theory. He demonstrated that scrapie infectivity
co-purified with a protein of 27-30 kDa molecular weight,61,62 and that this
infectivity was not dependent on polynucleotides.63 The apotheosis of these
experiments was the development of spontaneous neurodegeneration in
transgenic mice carrying the murine equivalent of the codon 102 mutation in
man.64 Transmission of brain tissue from these animals into Syrian hamsters
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and homotypic transgenic mice (but not Swiss mice) was successful.65,66 In
subsequent experiments PrP null mice were shown to be resistant to the
intracerebral inoculation of scrapie,67 and the "conversion" of soluble,
protease-sensitive prion protein (PrPc) to its protease-resistant, infective form
(PrPSc) was achieved in a cell-free system.68 Taken together, these
experiments provide compelling evidence for the primacy of PrP in the
pathogenesis of the spongiform encephalopathies. The interaction of PrPc
with PrPSc may enable the formation of more PrPSc (Figure 3). As well as
mediating neurotoxicity, PrPSc may then convert more PrPc to PrPSc. The
theory is less effective in explaining the strain variability observed with
scrapie, which is intuitively attributed to the agent including nucleic acids.69 In
order to accommodate the protein-only model and this observation, a "virino"
model has been proposed. In this an essential but small nucleic acid
component is protected by its close and integral association with PrP.70
Alternatively, a "coprion" or "unified" theory postulates that although the
agent itself is devoid of nucleic acid, it has the capacity to recruit cellular
nucleic acid from the cell which it is infecting for replication.71 Others,
including Prusiner, have argued that the "variability" of the agent resides in
glycoprotein modifications of the basic prion molecule,72 or in conformational
differences in the p-pleated quaternary structures of PrPSc.73
The strongest evidence to support the prion hypothesis has arisen from the
study of inherited forms of CJD. To date, 22 separate mutations of the open
reading frame (ORF) of the encoding gene of PrP have been linked with
cases of inherited CJD (Table 4). Mutations have not been identified in
normal controls,75,95 and furthermore there have been no reported cases (so
far) of inherited CJD worldwide not associated with any of the mutations
identified.
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The ease with which transmissibility is achieved according to this model is
clearly dependent on the homotypic similarities between interacting prion
proteins. It is suggested that the lower rate of successful transmission of
inherited cases of CJD to experimental animals41 is due to the difficulty PrP
molecules derived from mutated alleles will have in interacting with "normal"
PrP of the inoculated animal. Sporadic CJD is thought to arise from the
chance conformational change of PrPc to PrPSc. Some evidence for this is
available from the observation that transgenic models in which prion protein
is over-expressed have spontaneously developed transmissible spongiform
encephalopathy.96
In a recent development on the prion theme the presence of a "protein X",
which may act as a molecular chaperone in the formation of PrPSc, has been
postulated.97 The presence of this species-specific macromolecule may
account for the need for ablation of the nascent PrP gene before transgenic
mice expressing human PrP become susceptible to exogenous human prions.
3.2 PRNP, its role in iatrogenic and sporadic CJD, and further implications
on the prion theory
The PRNP ORF has a site of common polymorphism at codon 129. At this
site the amino acids methionine (Met) or valine (Val) are encoded.
Homozygosity in general appears to confer increased susceptibility to the
development of both iatrogenic and sporadic forms of CJD.98,99 In iatrogenic
disease, valine homozygosity appears to favour the development of CJD
when the agent is introduced outside the central nervous system (such as in
HGH recipients), whereas in cases of "central" inoculation (infected dura
mater graft recipients and the like) methionine homozygosity is favourable.100
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It is methionine homozygosity again that is strongly implicated in sporadic
CJD, being identified in around 80% of cases in Caucasian sporadic CJD
series.101,102 In one series, patients who encoded Met/Val at codon 129 had a
median disease duration of 8.8 months, compared with median disease
durations of 3.0 and 6.0 months respectively in Met/Met and ValA/al-encoded
patients.101 However, the number of patients carrying Val-encoding alleles
was small in number (12 out of a total of 41 cases). It is also of note that in
one large pedigree with inherited CJD, the age at death was influenced by
this polymorphic site: carriers who were heterozygous at this site had a
significantly greater age of death compared with those who were
homozygous at this site (the mutation in this pedigree was always carried on
Met-bearing alleles).95 Once more these observations have been interpreted
as being consistent with the prion theory, in that PrP molecules that are
derived from PRNP genes that are homozygous at codon 129 will have an
enhanced capacity for polymerisation, whereas PrP molecules derived from
patients who are heterozygous at codon 129 will exhibit less efficient
polymerisation. In the latter case, therefore, the disease will progress less
rapidly, and patients will be afforded a degree of "protection" from disease
development (hence their older age at death).
3.3 Familial CJD
In this section, the various forms of inherited CJD linked with mutations of
PRNP are examined from a clinical perspective. Large scale population-
based series in which mutations of PRNP were screened for, revealed that
the true prevalence of familial CJD was between 11 and 13%.101,102 This, it
will be recalled, is roughly twice that estimated in epidemiological studies in
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which a positive family history (of CJD) was the only criterion for
consideration as a case of inherited CJD.
Although early descriptions attempted to correlate specific clinical and
neuropathological phenotypes with particular PRNP mutations,103 with greater
experience it became clear that there was considerable variation especially in
the clinical manifestations.104,105 The attempt to analyse this phenotypic
variability on the basis of the common polymorphism at codon 129 has
yielded mixed results.106,107
3.3.1 Pro - Leu change at codon 102, and GSS
As described earlier, this was the first identified pathogenicity-associated
PRNP point mutation. Although the initial publication claimed "linkage" with
GSS (maximum lod score of 3.26),25 it is now thought that the mutation itself
is pathogenic.108 It has been identified in a number of kindreds with familial
CJD worldwide. It has also emerged that the clinical and pathological
phenotypes associated with this mutation are highly variable. For example, in
the German "Sch" pedigree, although the clinical illness was broadly
consistent with GSS, specific clinical features varied significantly.109 It was of
note that one patient presented with anxiety and poor concentration, and
others exhibited titubation and myoclonus during the clinical illness, all
unusual features in GSS. Multicentric amyloid deposits were present in all
autopsied cases, but there was a striking variation in the extent of spongiform
change. The evaluation of the impact of other sites of genetic influence on
this phenotypic variability is in progress, but, as mentioned, codon 129 has
not been shown to influence phenotypic variability in an Italian pedigree.107
The final and most confusing issue with regard to GSS is the variety of PRNP
mutations that are associated with this pathological phenotype. For example,
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the point mutation at codon 117 was first described in association with GSS
in Japan,75 and the point mutations at codons 198 and 217 are associated
with a form of GSS in which, in addition to multicentric plaques, there are
neurofibrillary tangles ("the Indiana variant").80,84 It should be noted that the
codon 117 mutation has subsequently been described in association with a
so-called "telencephalic" form of CJD.76 In this form dementia is accompanied
by pyramidal and extra-pyramidal features, and cerebellar signs are present
to a variable extent.110 The Indiana variant is not clinically distinct from
GSS.111
In Japanese series, where the population prevalence of Val at codon 129 is
low (Met:Val = 0.958:0.042 compared with Met:Val = 0.625:0.375 in
Caucasian British),60 the presence of the triplet encoding Val is considered a
pathogenic point mutation, and the associated disease dubbed GSS.112 It is of
note, however, that the amyloid plaques in this form of CJD are unicentric
aggregations of prion protein, a form of prion protein deposition identified in
sporadic cases in the West (and more often seen in association with alleles
encoding Val at codon 129).113,114 It appears therefore that the amino acid
change Met to Val at codon 129 is not a "mutation" linked with GSS, but a
polymorphism associated with plaque-like deposits of PrP on
neuropathological examination. Curiously, like in GSS, ataxia tends to be a
key clinical feature in these patients worldwide, and characteristic EEG
appearances are encountered rarely.115,113
3.3.2 Glu - Lys change at codon 200
This mutation is of some historical interest, in that it appears to be the
explanation for the high incidence (sometimes more than 100-fold) of CJD in
certain ethnic groups. In the case of Libyan-born Jews, the high incidence of
CJD was attributed to dietary factors, in particular the consumption of lightly
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grilled sheep eyeballs.116 It is now known that clinical illness in this population
cosegregates with the codon 200 mutation.117 The mutation has been
identified in CJD clusters in Slovakia and Chile,118,119 and in ethnic British,
French and Japanese patients.120,121,122 The classical disease phenotype
associated with this mutation resembles sporadic CJD. As in sporadic CJD
characteristic EEG appearances are commonly encountered, and on
neuropathological examination typical spongiform encephalopathy is present.
Transmissibility is more readily achieved than with other forms of familial
CJD.41 Despite the superficial similarities in clinical, neuropathological and
transmission characteristics, a detailed study of a large Libyan Jewish
pedigree revealed considerable heterogeneity of clinical features, including
rarities (for CJD) such as demyelinating polyneuropathy.104,123 Another
affected member of the same pedigree with clinical and pathological features
of fatal insomnia (vide infra) has been reported.124 There is some debate on
the degree of penetrance of this mutation. Initially thought to 0.56
penetrant,125 it is now argued that it is (like all other PRNP mutations) fully
penetrant if the carrier lives sufficiently longU6
Other PRNP mutations with clinical phenotypes resembling sporadic CJD
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include the Val - lie change at codon 210 and the Asp - Asn change at
codon 178 (in association with Val at codon 129 of the mutation-bearing
78
allele). The latter mutation is not, however, associated with characteristic
EEG appearances.103 It also emerges, fortuitously, as the first clinically
described pathogenicity-associated PRNP mutation: an identical mutation
127
was demonstrated in DNA extracted from archival material on the first case
of familial CJD ("Paul Backer"), described by Kirschbaum in 1924.128
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3.3.3 Fatal Familial Insomnia (FFI)
The syndrome was first described in 1986 by Lugaresi et a/.129 A 53-year old
man presented with progressive insomnia and dysautonomia. A previously
sound sleeper, he could only sleep for two to three hours at night. Fie became
impotent and had loss of libido. There was episodic salivation, lacrimation
and rhinorrhoea, and he exhibited orthostatic diaphoresis, pyrexia, difficulties
with micturition and constipation. Two months later, he could sleep for only
an hour each night, and he was frequently disturbed by vivid dreams. Fie
developed progressive dysarthria, intention tremor of his limbs and gait
ataxia. Examination at this stage revealed miosis, cerebellar signs and brisk
tendon reflexes. He was noted to lapse into a stuporose state if left alone, in
which he performed complex and apparently purposeful gesturing and
breathed noisily. He could be awakened quickly by light stimuli. As his
condition progressed, there were oculomotor disturbances (limitation of
upward gaze and saccadic movements), myoclonus, and irregular breathing
patterns. Terminally he became confused and disorientated, had episodes of
motor agitation, and exhibited severe truncal dystonias. The total duration of
his illness was nine months.
Routine laboratory investigations were normal, with the exception of mildly
elevated CSF protein (0.76 g/l) and elevated urinary catecholamines. EEG
was not characteristic of CJD, but revealed diffuse slow waves and latterly
became isoelectric. His dreamlike states coincided with EEG
desynchronisation, but physiological EEG patterns of sleep were absent. A
pharmacological response to a short-acting benzodiazepine antagonist could
be demonstrated both clinically and electrophysiologically.
Examination of his pedigree revealed at least four other affected family
members, including two sisters of the propositus.
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Neuropathological examination revealed severe cell loss and reactive
astrocytosis of the anterior and dorsomedial nuclei of the thalamus. There
was some astrogliosis of the olivary nuclei in addition, but the neocortex and
white matter were entirely normal with no evidence of spongiform
encephalopathy. Similar neuropathological findings were found when tissue
from one of the sisters of the propositus was re-examined.
The causation of this unique inherited neurodegenerative process remained
unknown until 1992, and the identification of the codon 178 (Asp - Asn)
PRNP mutation in affected members of this pedigree.7 By then the family had
been studied in greater detail, and it had become apparent that in addition to
insomnia and dysautonomia, dysarthria, ataxia, myoclonus and pyramidal
signs were invariably present in affected members. Memory and attention
deficits were minimal in the early stages, but tended to progress with time.
During "sleep" there was loss of the slow-wave and rapid-eye-movement
phases. The mean age at onset was 49 years, and the mean duration was 13
months.
More extensive neuropathological evaluation revealed various degrees of
atrophy and reactive astrogliosis in the cerebral and cerebellar cortices, in
addition to the selective thalamic and olivary degeneration noted before.
Spongiosis of the cerebral cortex was noted in only one out of the seven
cases examined.
Although readily accepted as a form of inherited CJD, it was not known how
an identical PRNP mutation (Asp - Asn at codon 178) could produce such
diverse clinical and neuropathological phenotypes. (It will be recalled that the
mutation was first described in association with inherited CJD which was
phenotypically similar to sporadic CJD.) This issue was elegantly resolved
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later in 1992, when the common polymorphism at codon 129 was found to
determine the disease phenotype: when the allele bearing this mutation
encoded Met at codon 129 FFI was seen, whereas in association with Val
CJD was observed.106 There appear to be distinct differences between the
conformational structures of the respective mutant PrP molecules.130 Although
initial attempts at transmission of FFI were unsuccessful,41 this has recently
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been successfully carried out to laboratory mice and transgenic mice
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expressing human PrP.
3.3.4 "CJD" related to extra repeat insertions
The region between codons 51 and 91 of the PRNP ORF normally comprises
one nonapeptide and four octapeptide repeats.133 Insertions of two and
between four and nine extra octapeptide repeats have been associated with
CJD.858687 8"4 Phenotypically, these cases appear to resemble CJD, with two
notable exceptions. Firstly, in the large pedigree reported from the South
East of England with a 144 base pair insertion (six extra repeats), there was
striking diversity in the clinical phenotypes of affected cases.89 Diagnoses
such as General Paralysis of the Insane, "spinal sclerosis", "cerebral
softening", cerebral thrombosis, dementia praecox, Parkinsonism,
Huntington's disease, Pick's disease and ATD had been attached to affected
members of the pedigree through the ages. This was accompanied by
considerable variation in the neuropathological features of cases. At one
extreme the changes of CJD were so typical that sections were used to
illustrate spongiform encephalopathy in Greenfield's textbook of
neuropathology, and at the other extreme no abnormalities were present
except on immunocytochemistry.134,135 The final point of note in this family
was that the nucleotide sequence of the mutated allele had remained stable
95
over at least six generations. This contrasts with neurodegenerative
processes associated with trinucleotide repeat sequences, where there are
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expansions of repeat sequences in successive generations.136 This molecular
biological mechanism appears to correlate with the clinical phenomenon of
anticipation, where carriers in successive generations are affected at an
earlier age (and more severely). Anticipation is not a feature of inherited CJD.
Secondly, in their report on a case of dementia associated with a 216 base
pair insertion (nine extra repeats), Duchen et al argued that the presence of
neuritic plaques staining positively for p-amyloid protein and tau protein
indicated that this case represented a transition (neuropathologically, at
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least) between CJD and ATD. From the clinical perspective, however, this
patient's illness was entirely compatible with familial CJD.
3.3.5 Pro - Leu change at codon 105, and the amber mutation at codon 145
These mutations were described in familial cases of CJD in Japan. Almost
uniquely for cases of CJD (sporadic or familial) patients carrying the mutation
at codon 105 presented with spastic paraparesis.74 Dementia eventually
supervened, but there were no cerebellar features or myoclonic jerks.
Characteristic EEG appearances were not seen. Neuropathological
examination revealed amyloid plaques (hence the designation "GSS"), and
vacuolation with loss of myelin of the pyramidal tracts in the brainstem and
spinal cord. As indicated, spinal cord features are rare in CJD both clinically
and pathologically, although recently PrP has been detected by
immunocytochemistry in the spinal cords of sporadic and HGH-associated
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cases.
The mutation at codon 145 leads to the generation of a "stop" codon, and
was clinically associated (in a single patient) with a slowly progressive
dementia (greater than 10 years' duration).77 Neuropathology revealed no
spongiform change, but there were anti-PrP positive amyloid plaques
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(negative with anti-pA4 antibody), hence its designation as "GSS". Elegant
immunocytochemical studies have shown that the amyloid plaques in this
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case contain only the N-terminal of PrP. If the prion hypothesis is accepted,
the implication of this observation is that the polymerisation of PrP molecules
in this setting is limited to mutant molecules. This is analagous to the
transmission characteristics of tissue from the murine GSS model, where
successful transmission was achieved only where the recipient also carried
the codon 101 mutation. Presumably the interaction requires recognition of
homologous PrP molecules.
In the foregoing descriptions, the spectrum of clinical and pathological
phenotypes associated with PRNP mutations have been explored. While
providing an invaluable tool for the investigation of familial
neurodegeneration in general and familial CJD in particular, there are
dangers in attributing rigid clinical definitions to individual mutations. Not only
is this over-simplistic, but such attempts may ignore the influence of
modifying genes on PRNP. As noted in the case of the common
polymorphism at codon 129, modifying mechanisms may even be contained
within the same ORF.
The apolipoprotein E (APOE) gene has emerged as another possible
disease-modifier. Following the observation of this gene's influence on
ATD,139 cortical Lewy body disease140 and Down's syndrome,141 studies are in
progress to examine the influence of the APOE gene on CJD. In a French
study, the s4 allele of the APOE gene was found to be a risk factor for the
development of CJD, and a subgroup analysis of 14 patients (out of a total of
61) bearing the s2 allele revealed that these patients had a longer disease
duration.142 The study has subsequently been criticised for its inappropriate
selection of controls,143 and in the hands of a second (German) group APOE
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gene status did not influence the development or outcome of CJD.144
Apolipoprotein E in the CSF was also examined, with normal results.144 In the
study by Pickering-Brown et al in which 8 out of 20 patients had amyloid
plaques, the presence of the s2 allele was associated with a later age of
onset.114 It is conceivable that the influence of the APOE gene in CJD is
predominantly on the subset of patients who manifest amyloid plaques. This
is biologically plausible, in that APOE is a constituent of PrP amyloid plaques.
It is finally worth considering the normal function of PrP. PrP null mice were
found to develop normally and have normal gross behavioural
characteristics.145 This was a surprising finding given the high conservation of
PrP among mamalian species and its wide expression in early embyogenesis.
Recently it has been demonstrated that PrP null mice exhibit weakened y-
amminobutyric acid type A receptor-mediated fast inhibition and long-term
potentiation.146 The relevance of this observation to the underlying pathogenic
processes in CJD is unclear at present. Of more obvious relevance (in view
of the clinical observations in FFI) is the recent description of altered
circadian activity rhythms and sleep patterns in these mice.147
4.1 Iatrogenic CJD
CJD acquired by iatrogenic mechanisms is extremely rare, with the total
number of cases worldwide currently numbering less than 120. Nevertheless,
in addition to the public health implications, these cases are important for the
insights they have given into the mechanisms by which spongiform
encephalopathies develop and propagate. Iatrogenic CJD has been shown to
arise from five main sources:
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4.1.1 Human pituitary-derived hormones
Since the first descriptions of CJD in recipients of HGH in 1985,148,3 more
than 75 cases have been identified. In addition, there have been at least two
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cases associated with gonadotrophin (HGnH) therapy. Up until 1985 these
hormones were derived from human cadavers, and, for example in the case
of HGnH, up to 800 cadaveric pituitary glands pooled in a single batch of
treatment.150 The outbreak of cases in the US, Britain and France implies that
multiple independent contaminations took place.
In contrast to patients with sporadic and familial CJD, the clinical illness in
these patients is strikingly homogeneous. The disease is characterised by a
progressive cerebellar syndrome, with little or no cognitive impairment at the
start and the absence of typical EEG appearances.151 For example, in their
clinical descriptions of 1985, the physicians from San Francisco and
Bethesda both highlight the insidious development and relentless
progression of truncal and limb ataxia in their patients.148,3 Both patients
exhibited personality change at the start of their illnesses, in particular
appearing apathetic and unconcerned about their predicament. As the
disease progressed titubation, limb rigidity, myoclonus (including startle
responses) and bulbar dysfunction supervened. Terminally, the patients were
probably demented, and were akinetic and mute. In some respects the
clinical courses of these patients were similar to those described in kuru,
particularly in children (vide supra). This similarity has led to the suggestion
that it is the peripheral (outside the central nervous system) route of
inoculation of the CJD agent that leads to this clinical phenotype.
The putative "incubation period" after agent inoculation and disease
development is difficult to estimate, as HGH therapy was received as
injections twice or three times per week over many years. However, based on
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the mid-points of the respective courses of treatment, an estimate of 15 years
with a maximum of 30 years in a single case has been made.8 The durations
of clinical illness in the first described cases were 6 and around 18
months.148'3
The higher prevalence of valine homozygosity at codon 129 in patients with
iatrogenic CJD after the peripheral inoculation of agent has been mentioned
previously. The reason for this, or indeed why methionine homozygosity
should be favoured when the agent is inoculated centrally, is unclear.
4.1.2 Human cadaveric dura mater grafts
These grafts which were used in neurosurgery to repair dural defects, have
been implicated in at least 25 cases of CJD in graft recipients.152 The median
incubation period has been estimated to be around 67 months,48 and their
clinical illnesses on the whole have resembled sporadic CJD. The recent
clinical descriptions of four of these patients are notable.153 In all of them the
"Lyodura" grafts had been placed in the posterior fossa and they all
presented with cerebellar features (all four were ataxic at presentation, and
three had dysarthria). The cerebellar presentations in these patients may
have been related to the inoculation of agent into or near the cerebellum, or
due to the "decompensation" of function manifesting first at this site (two of
the patients had had cerebellar astrocytomas resected, and two had had
posterior fossa decompressions for Arnold-Chiari malformations). The
evolution of illness in all four, however, was quite distinct from that seen
HGH-related CJD cases, and one of the patients developed periodic triphasic
complexes on the EEG.
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4.1.3 Corneal transplantation
The first clinical description (in 1974) of person to person transmission of
CJD was following a corneal transplant.154 The donor and recipient had
clinical illnesses typical of CJD, and the diagnosis was confirmed
pathologically in both. Subsequent experimental studies have confirmed the
infectivity of corneas of animals inoculated with the CJD agent,155 and its
spread along visual pathways after intraocular inoculation.156 It is of note that
the recipient (who developed her illness 18 months after the procedure) had
lethargy, nausea and ataxia as her initial symptoms, and developed
dysphagia, myoclonus and brisk reflexes as the disease progressed.
Terminally she was mute and had decorticate posturing. Despite the
experimental studies referred to, cortical blindness was not a key feature.
4.1.4 "Contaminated" EEG depth electrodes and operating instruments
In 1977 two cases of CJD in individuals who had had stereotactic EEG
recordings were reported.157 The victims were aged 19 and 25, and it seemed
unlikely that they could both have developed sporadic CJD by chance. Two
of the electrodes used in both procedures had been used previously in a
patient with a four-month history of dementia, ataxia, involuntary movements,
myoclonic jerks and akinetic mutism, in whom CJD was confirmed
(subsequently) at autopsy. The heat sensitvity of the electrodes had
prevented their autoclaving, and they had been "sterilised" with 70% alcohol
and formaldehyde vapour. One of the electrodes has subsequently
transmitted CJD to a chimpanzee 18 months after intracerebral
implantation.158
Finally, a total of four cases in which CJD was probably acquired at the time
of neurosurgery have been reported.159,160 The three cases reported by Will
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and Matthews were of note for their inclusion in the descriptions of "subacute
vascular encephalopathy" by Nevin et al.
Iatrogenic cases of CJD, although insignificant in terms of numbers, have
contributed to the study of this enigmatic illness. The variable clinical
phenotypes associated with the different routes of inoculation is a particularly
pertinent observation. It is argued that with any exogenous (outside the
central nervous system) source of infectivity, the clinical phenotype will
resemble that in HGH recipients (with progressive cerebellar ataxia).161 These
speculations were lent enormous significance following the recent description
of a novel form of CJD in the UK.
5.1 New variant Creutzfeldt-Jakob disease (vCJD)
The description by Will and colleagues of a form of CJD with a unique and
hitherto unrecognised pathological phenotype probably extends the spectrum
of human spongiform encephalopathy.162 The original ten cases were
identified between March, 1995 and January, 1996 at the unit where the
current study was based. The cases were characterised clinically by an
unusually young age of onset for sporadic CJD (mean age at onset = 26.3,
median = 28, range = 16-39; n = 11 (data including a further pathologically
confirmed vCJD case from France163), a relatively long disease duration
(mean = 7 months, median = 13, range = 7.5-23), unusual presenting
features for CJD (such as sensory disturbance and "pure" psychiatric
features), atypical EEG findings, and absence of pathogenicity-associated
PRNP mutations and Met homozygosity at codon 129. Cerebellar ataxia was
a prominent feature in the majority of the patients' illnesses. The unifying
pathological feature in all cases was the widespread presence of prominent
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PrP plaques (termed "florid" plaques), which stained densely with anti-PrP
antibody. Attempts to identify similar pathology in central nervous system
tissue from previously diagnosed (including young) cases of CJD, in the UK
and elsewhere, has been unsuccessful.
The finding has fuelled the search for pre-mortem diagnostic tests, especially
where vCJD is suspected in young individuals. Even by immunoassay the
brain 14-3-3 protein in CSF appears to lack specificity in suspect CJD
cases.164 Meanwhile, Collinge and colleagues have demonstrated that the
physiochemical characteristics on Western blotting of PrPSc derived from
patients with vCJD are distinct from those of patients with sporadic CJD and
iatrogenic CJD related to HGH.165 The application of this technique to study
PrPSc in tonsil tissue (successfully, in a single vCJD case to-date) is a
promising development.166
In this introduction the early clinical descriptions of CJD have been reviewed.
The clinical data from large-scale epidemiological studies of this disorder
have then been summarised. The "prion" hypothesis has been described,
and the role of PRNP in sporadic, familial and iatrogenic CJD examined. The
spectrum of disorders associated with mutations of PRNP has been
described. The poor correlation between specific PRNP mutations and
clinical phenotypes has been noted. Furthemore, the association of PRNP
mutations with cases of familial CJD has led to the expansion of the clinical
boundaries of this disorder. The clinical presentations of the small number of
cases of iatrogenic CJD have been reviewed, and particular note made of the
phenotypic differences between cases in which inoculation occurs inside and
outside the central nervous system. Finally, reference has been made to
vCJD.
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Inevitably, a completely comprehensive review of the clinical manifestations
of CJD is impossible. For example, cases presenting acutely (resembling
strokes)167 and those found in association with ATD168 have not been
discussed. All researchers of the disorder are aware of the immense diversity
of clinical features, and the medical literature is replete with descriptions of
unusual presentations of CJD.This study is one means of identifying exactly
how common these unusual phenotypes of CJD are. Also it can be
ascertained whether the phenotypic expressions of the patients in this series
vary significantly from those included in previous descriptions. Speciation
along clinical grounds, if feasible, will enable correlative studies between
clinical phenotypes on the one hand and neurpathological and molecular
biological characteristics on the other. Systematic data on CJD in the UK
between 1990 and 1994 will also act as a useful background against which





All patients in the study were referred to the U.K. national surveillance unit,
as suspected cases of CJD. The study design has been reviewed,169 and has
been adopted in the Biomed I programme for the surveillance of CJD in the
European Community.170 In order to ensure comprehensive coverage and
avoidance of bias, a variety of sources are requested to refer cases. Briefly,
suspected cases of CJD were referred by Neurologists, Physicians and
Psychiatrists during the terminal illness. Cases manifesting typical EEG
appearances were referred by Neurophysiologists. The patients were visited
by a neurologist (RGW, TFGE, RDS or MZ) attached to the unit, and data on
the evolution of the illness was collected by interview of a close relative or
friend, and perusal of clinical records. The patient was examined, and results
of investigations collected from the case sheet. Where possible
electrophysiological and imaging studies were reviewed personally. Blood
was collected from patients for storage and extraction of DNA for PRNP
genome analysis. The latter was performed after appropriate counselling of
relatives, in line with guidelines.171 Post mortem confirmation is sought in all
cases, and this is achieved in almost 70% of cases referred to the unit.172
Neuropathology colleagues are another source of referral. Cases that were
found to have CJD at post mortem were referred to the unit, and clinical
information collected from interview of relatives and examination of records
retrospectively. The Office of Population, Census and Statistics acts as a final
check, and all death certificates carrying rubrics suggestive of CJD were
screened and forwarded to the unit. The case records of these cases were
examined, and if the diagnosis of CJD could be sustained clinical information
was collected retrospectively again.
The study is part of the effort to detect any influence of the epidemic of BSE
on the incidence and characteristics of CJD. Therefore, in addition to
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gathering clinical data, a detailed questionnaire on patients' lifestyles was
completed. In this, information on family history, occupation, animal exposure,
diet and residence was collected from cases and age and sex-matched
controls. Results of this on-going epidemiological study are published
annually.172,161,173
The cases were classified according to standardised criteria, modified from
Masters et al,38 Definite cases have been confirmed pathologically, either by
examination of the whole brain after autopsy or following brain biopsy.
Probable cases have not been confirmed pathologically, but have
characteristic EEG tracings (periodic sharp wave complexes throughout the
recording) in an appropriate clinical context. The latter is defined as a rapidly
progressive dementia in a patient with at least two of the following clinical
features: myoclonus, cortical blindness, pyramidal/extrapyramidal/cerebellar
dysfunction, akinetic mutism, and early neurogenic muscle atrophy. Possible
cases have not been confirmed pathologically and do not manifest typical
EEG appearances, but they have had a rapidly progressive dementia with at
least three of the clinical features listed. At post mortem, patients suspected
of having CJD may turn out to have succumbed to another
neurodegenerative process: these patients have been classified as "other" in
the current study. A further group of patients (other#) who at the time of
referral did not fulfil criteria for inclusion as either a probable or possible
case, and for whom a final tissue diagnosis was unavailable (usually because
of recovery or lack of progression of the clinical illness) was identified, for
comparison with the patients designated other.
The patients in this study were referred consecutively to the unit between
May, 1990 and the end of April, 1994 (representing the first four years of the
surveillance project). The patients seen by each neurologist have been listed
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in Appendix 1. The clinical information was compiled at the time of the visit in
a standardised pro-forma, and for the purposes of this study clinical data from
all definite, probable, other and other# cases identified during this period was
extracted by RDS. The sign(s) at presentation, the clinical characteristics
during the early phase, and during the course of the illness were listed
separately (Appendix 2). The presence or absence of specific features was
recorded as a binomial variable (presence = "1", absence = "0"). Other
clinical variables such as age at onset (which was estimated as accurately as
possible from the clinical enquiries) and disease duration were listed as
continuous variables in a database created on the C-Stat for Windows
package. Other information included in the database were: class ("1" =
definite, "2" = probable, "4" = other),* type ("1" = sporadic CJD, "2" = familial
CJD, "3" = iatrogenic CJD), presence/absence of PRNP mutation, genotype
at codon 129, and EEG/liver enzyme/CSF/neuroimaging data ("1" =
abnormal, "2" = normal). The CJD reference number (the patient identification
number in use at the unit), and the unit neuropathology reference number (in
those cases where the neuropathological examination had been performed in
Edinburgh) were also listed. In familial cases, further clinical information
particularly pertaining to family history was gathered directly from the records.
In the process of collecting the data, particularly interesting investigation
results were highlighted, so that these could be discussed later in the study in
greater detail.
Comparison of ages of onset and disease durations between the different
types of CJD were carried out using Mann-Whitney U tests. Analysis of
clinical characteristics at different stages of the illness was performed
separately in sporadic, familial and iatrogenic cases. Using this data an
*
Class 3 or "possible" cases of CJD were not considered further in this study. An explanation for this
omission is given, and the possible consequences explored, in the discussion section (page 68).
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attempt was made to identify particular CJD phenotypes, for example
Heidenhain's variant, CJD with progressive cerebellar ataxia, and CJD of
long duration. Comparison of clinical characteristics between different forms
of CJD was performed using Spearman rank correlation. The clinical features
during the course of illness in definite and probable cases were compared
with those in cases classified as other using standard tests of sensitivity and
specificity. Of course, at the time a patient is referred to the unit, their final
outcome (in terms of death, stability or recovery) is unknown. In order to
validate the sensitivities and specificities of the clinical features, in separating
cases of CJD from those that are not at the time the signs are elicited, a
further comparison was undertaken between other and other# cases.
2.1 Neuropathology
Neuropathological examinations were sometimes performed at other centres.
The following protocol was used for the examination of tissue at the
surveillance unit. After fixation of the brain in 10% formalin, tissue blocks
were obtained from all cortical areas, the basal ganglia, thalamus,
hypothalamus, cerebellum and brainstem. The blocks were decontaminated
in 96% formic acid before routine processing into paraffin wax. Five pm
sections were cut and stained by conventional histological techniques and by
immunocytochemistry for prion protein using a polyclonal antibody raised
against scrapie-associated fibrils (courtesy of Dr. J. Hope, MRC/AFRC
Neuropathogenesis Unit, Edinburgh). Histological examination was kindly
performed by Drs. Jeanne Bell and James W. Ironside.
In correlating clinical features with sponge distribution, the clinical data from
individual cases was condensed and the area(s) of brain most likely to be
38
impaired, based on conventional knowledge of function localisation,
was(were) identified. The corresponding histological report was perused
blindly, and areas of brain showing spongiform change identified, based on
the description of sponge distribution in the report. The degree of consistency
between reports was inadequate to allow quantification of spongiform
change. Clincal and pathological correlation for each area of brain was
performed by comparing (in 2 X 2 tables) the frequency with which clinical
features and spongiform change co-existed. Cases showing anti-PrP positive
plaques were identified for correlation with clinical and molecular biological
features.
3.1 Molecular biology
Genomic DNA was extracted using standard procedures, and the single
PRNP exon encoding the entire ORF was amplified by polymerase chain
reaction (PCR). The amplification reaction (in a final volume of 50 pi)
contained 100 ng of the genomic DNA, 50 mM KCI, 10 mM Tris-HCI (pH 9.0),
0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM of each deoxynucleotide
triphosphate, 1 pM of each oligonucleotide primer and 2.5 units of Amplitaq
(Perkin Elmer Cetus). The sequence of the oligonucleotide primers were 5'-
CGCAAGCTTGAACTCTGACATTCTCCTCTTC-3' (primer A) and 5'-
TTCGAATTCCTCCCTCAAGCTGGAAAAAG-3' (primer B), which are situated
5' and 3' to the human PRNP ORF respectively. The mixture was overlaid
with 100 pi mineral oil and subjected to 35 temperature cycles (T 95°C, 1'
50°C, 1' 72°C) in an Omnigene thermal cycler. To analyse and purify the PCR
products, the reaction was loaded on a 1.5% agarose gel, electrophoretically
separated and stained with ethidium bromide. The amplified PRNP ORF was
eluted according to standard procedures and subjected to (.1) single-strand
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conformational polymorphism (SSCP) analysis,174 (.2) direct sequencing or
sequence analysis following cloning and (.3) a modified direct sequencing
protocol175 for fast screening of several known mutations and the common
polymorphism at codon 129.
3.1.1 To detect mutations, SSCP analysis was performed. 5 ng of the
amplified, eluted PRNP ORF was reamplified with each of the following pairs
of oligonucleotide primers to generate a set of four overlapping products
covering the whole ORF:
Pair 1: S'-CTGACATTCTCCTCTTC-S' (primer C) and
5'-TTGTTCCACTGACTGTG-3' (primer D);
Pair 2: 5'-GCCCTGGAGGCAACCGC-3' (primer E) and
5'-GTAGCCGCCAAGGCCCC-3' (primer F);
Pair 3: 5'-TGGCACCCACAGTCAGT-3' (primer G) and
5-TTCTCCCCCTTGGTGGT-3' (primer H);
Pair 4: 5'-CGTGAAAACATGCACCG-3' (primer I) and
5'-CCTCAAGCTGGAAAAAG-3' (primer K).
Apart from the choice of primers, the PCR conditions were different to the first
round of amplification in containing 2.5 pCi of (a -32p)-dCTP (Amersham)
with cycling conditions of 0.5' 95°C, 1' 40°C, 2' 72°C. 2 pi of the reaction was
mixed with 9 pi of stop solution (95% formamide and 10 mM NaOH), heated
to 95°C for 2', flash-cooled on ice and 2 pi of this sample loaded on to a
Hydro-LinkTM gel (AT Biochem), that was prepared and run according to the
manufacturer's recommendations. The radioactively labelled products were
detected by autoradiography and mutations in specific samples were
revealed in comparison with normal PRNP ORF by changes in the migration
pattern due to point mutations, deletions or insertions.
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3.1.2 The exact nature of the changes in SSCP analysis was determined
either by direct sequencing of the the amplified and gel-purified PRNP ORF
with Circum Vent™ polymerase (New England Biolabs, according to the
manufacturer's recommendations) or by sequencing with Sequenase Version
2.0 T7 DNA Polymerase (USB) following cloning in pBluescript IIKS(-)
(Stratgene). The cloning was done by standard procedures making use of the
Hindlll and the EcoR1 site in the primers A and B, respectively. To exclude
PCR artefacts the products of three independent PCR reactions were
analysed in parallel. The sequencing primers were the synthetic
oligonucleotides used in the SSCP analysis (primers C to K).
3.1.3 Fast screening for the known mutations at codon 102, 178 and 200
and for the common polymorphism at codon 129 was done by a modification
of the direct sequencing protocol. The synthetic oligonucleotides primer G, 5'-
CTGCTCATGGCACTTCC-3' (primer L), 5'-GATTGTGATATTGACGC-3'
(primer M) or 5'-CAAGGGGGAGAACTTCA-3' (primer N) were used for
revealing the genotype at codon 102, 129, 178 or 200 respectively, and were
radioactively labelled at their 5' end with (y -32p)_ATP and T4 polynucleotide
kinase according to standard procedures. 1.2 pmole of the labelled primer
was mixed with 10 ng amplified, gel-purified PRNP ORF and 2 units of
VentR™(exo-) DNA polymerase (New England Biolabs) in 10 mM KCI, 10
mM (NH4)2S04, 20 mM Tris-HCI (pH 8.8), 5 mM MgS04 and 0.2% Triton X-
100 made up to a final volume of 15 pi. 3.2 pi of this mixture was added to 3
pi of a nucleotide mix, containing either 100 pM dATP, 100 pM dCTP, 100 pM
dGTP and 720 pM ddTTP (in the case of primers G, L and M) or 100 pM
dATP, 100 pM dCTP, 100 pM dTTP and 720 pM ddGTP (in the case of
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primer N). The reaction was then overlaid with 100 pi mineral oil and the
primer was elongated and simultaneously terminated at the polymorphic
position by subjecting it to 25 cycles of PCR (20" 95°C, 20" 37°C, 20" 72°C).
After adding 4 pi stop solution, 2 pi of the reaction were loaded on a 10% 7M
urea polyacrylamide gel. Depending on the homozygous or heterozygous
genotype of the patient, one or two products were created, which were
separated by electrophoresis and visualised by autoradiography.
The techniques were developed by Drs. Otto Windl and Peter Estibeiro, and
Prof. Rick Lathe at the AFRC Centre for Genome Research, University of
Edinburgh. TFGE and the author extracted DNA from all the analysed cases,
and the specialised molecular biological techniques were performed by Ms.
Maureen Dempster and other scientists at the AFRC Centre for Genome
Research. The author assisted the scientists in their laboratory on a number
of occasions, discussed the techniques with them and participated in the data
analysis.
Twenty-six patients in this study had their molecular biological examinations
performed at the Prion Disease Group, at St. Mary's Hospital, London
(Appendix 3). Their methodology was as follows.
The PRNP open reading frame (ORF) was PCR amplified from 1 pg genomic
DNA. The reaction included 25 pmol oligonucleotide primer, 50 mM Kcl, 10
mM Tris-HCI (pH 8.3), 1.5 mM MgCl2, 0.01% gelatin, 200 mM each
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deoxynucleoside triphosphate, 5% DMSO and 2.5 units Taq polymerase
[Amplitaq, Perkin Elmer Cetus] in a total volume 100 pi; cycling was: 94°C, 5
min; 35 cycles of [94°C, 30s; 57°C, 30s; 72°C, 60s]; 72°C, 5 min in a Techne






(for detection of insertions and deletions).
10 pi of product (oligos 5 and 6) were resolved by gel electrophoresis (1%
agarose); band sizes were compared with controls (normal alleles, alleles
with insertions or deletions in the octapeptide repeat region). Products
amplified with oligos 2 and 3 were first quantitated (agarose gel
electrophoresis); equal loadings were selected. In general 10 pi was
denatured (40 pi NaOH, 25 mM EDTA, 5 min), neutralised (50 pi 0.6 M Tris-
HCI [pH 7.4], 1.5 M NaCI), and vacuum blotted to nitocellulose (Hybond-N,
Amersham). After baking, filters were prehybridised in 6 x SSPE (0.9 M NaCI,
60 mM NaH2P04, 6 mM EDTA; pH 7.4), 0.1% BLOTTO (fat free powdered
milk), 0.1% SDS, 1 mM EDTA, 100 pg/ml denatured salmon sperm DNA,
36°C, 3h. Filters were hybridised for 16h under the same conditions in the
presence of 106 dpm/ml [32P] end-labelled oligonucleotide, one pair for each
as listed below. Filters were washed (3 M tetramethylammonium chloride, 50
mM Tris-HCI [pH 8.0], 2 mM EDTA and 0.1% SDS, 36°C, 15 min; followed by
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two further washes at 47°C, 15 min) prior to autoradiography for 4h. Allele-
specific hybridisation with the following oligonucleotides was performed to
detect all known mutations and polymorphisms of PRNR
Oligo 13: 5'-CTTCACCAAGACCGA-3' (LYS 200)
Oligo 14: 5'-CTTCACCGAGACCGA-3' (GLU 200)
Oligo 15: 5'-AACAAGCCGACTAAG-3' (PRO 102)
Oligo 16: 5'-AACAAGCTGAGTAAG-3' (LEU 102)
Oligo 17: 5'-CGGCTACATGCTGGG-3' (MET 129)
Oligo 18: 5'-CGGCTACGTGCTGGG-3' (VAL 129)
Oligo 26: 5'-GCTGCAGCAGCTGGG-3' (ALA 117 Pvull+)
Oligo 27: 5'-GCTGCAGCGGCTGGG-3' (ALA 117 Pvull-)
Oligo 28: 5'-GCTGCAGTGGCTGGG-3' (VAL 117 Pvull-)
Oligo 25: 5'-GCTGCAGTAGCTGGG-3' (VAL 117 theoretical)
Oligo 31: 5'-GAGAACTCCACCGAG-3' (PHE 198)
Oligo 32: 5'-GAGAACTCCACCGAG-3' (SER 198)
Oligo 36: 5'-ATCACCCGGTACGAG-3' (ARG 217)
Oligo 37: 5'-ATCACCCAGTACGAG-3' (GLN 217)
Oligo 38: 5'-GGGGCTTGGCGGCTA-3' (GLY 124: polymorphism
GGG)
Oligo 39: 5'-GGGGCCTGGCGGCTA-3' (GLY 124: polymorphism
GGC)
Oligo 47: 5'-AGTAAGCCAAAAACC-3' (PRO 105)
Oligo 48: 5'-AGTAAGCTAAAAACC-3' (LEU 105)
Oligo 49: 5'-AGTGACTATGAGGAC-3' (TYR 145)
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Oligo 50: 5'-AGTGACTAGGAGGAC-3' (STOP 145)
Oligo 51: 5'-GACTGCGTCAATATC-3' (VAL 180)
Oligo 52: 5'-GACTGCATCAATATC-3' (ILE 180)
Oligo 53: 5'-TCGAGCATGGTCCTC-3' (MET 232)
Oligo 54: 5'-TCGAGCAGGGTCCTC-3' (ARG 232)
Oligo JC14: 5'-TGTGCACGACTGCGT-3' (ASP 178)
Oligo JC15: 5'-TGTGCACAACTGCGT-3' (ASN 178)
Coordinates within the PRNP gene of the other oligonucleotides used in this
method were: Oligo 3, 85-111; Oligo 2, 840-816; Oligo 5, 100-124; Oligo 6,
448-427 (coordinates according to Kretzschmar et al.176).
The techniques were developed by Prof. John Collinge and Dr. Mark Palmer,
and applied by Tracy Campbell and Katie Sidle.
During the last year of this study (from May, 1993 to end-April, 1994)
following counselling of relatives by the author prior to obtaining blood for
PRNP genome analysis, they were requested to indicate whether the result of
the analysis should be made known to them. This was the recommendation of
a MRC-sponsored meeting into the ethical issues surrounding PRNP analysis
in cases of CJD (where the possibility of a mutation being found in the
absence of a family history of neurodegeneration existed). The responses
were noted for analysis.
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Comparison of codon 129 status between definite/probable and other cases
was performed by Chi-square. Clinical, electrophysiological and
neuropathological characteristics of sporadic CJD cases encoding Met/Val at
codon 129 of the PRNP ORF were considered, and compared with cases
homozygous at this site using Chi-square. The same statistical technique was
used to analyse the requests for results of genome analysis by relatives.
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RESULTS
1.1 The study population
Between May, 1990 and April, 1994, 418 cases were referred to the U.K.
national surveillance unit. The sources of referral have been described
previously, and all suspect cases were British. Of these, a total of 241 cases
were identified as being suitable for the current study. One hundred and
seventy had definite or probable CJD, 41 cases were classified as other and
30 cases as other# (vide supra). The number of males:females in the definite
and probable group was 73:97 (approximate ratio 1:1.3). The definite and





The incidence of CJD in the U.K. over the period of study was therefore
0.773/million/year.
The ages of onset and disease durations of sporadic, familial and iatrogenic
CJD are tabulated in Table 5. The number of patients for whom information is
available in each group is indicated in parenthesis. Patients with familial
disease presented about ten years earlier, and had disease durations
approximately twice as long as patients with sporadic disease. As might have
been anticipated, patients suffering from iatrogenic disease were younger,
but their disease durations were not significantly longer than in sporadic
cases. The clinical features of each of these groups are analysed separately.
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2.1 Sporadic CJD
The distribution of the age of onset of sporadic CJD cases is shown in Figure
4. The distribution appears bimodal, with two peaks centred around the mid-
sixties and mid-seventies. There is no increase in the number of cases with
increasing age, and this remains true even after adjustment for the falling
population with age (data not shown). The clinical, neuropathological and
molecular biological characteristics of the patients in the two groups did not
vary. There was a weak correlation between age of onset and disease
duration, with younger patients tending to survive longer (r - 0.2822, p =
0.0008; Figure 5).
2.1.1 Clinical characteristics
The first clinical sign or signs, the early clinical features and the features
noted during the course of the illness are tabulated in Table 6. The
characterisation of cognitive impairment requires some clarification. Given
the rapidly progressive nature of the illness, at the time patients were
examined they were usually globally demented and the identification of
specific neuropsychological deficits was impossible. The decision on which
aspects of cognition were impaired at presentation and at different stages of
illness was based retrospectively on the appraisal of case records. Using
these recorded observations, the author decided which of four crude
modalities of cognition had been affected (personality, behaviour, memory
and orientation). In the analysis of these data, in addition to considering what
proportion of patients had each specific aspect of impairment at different
stages of disease, an overall estimate of what proportion had some aspect of
cognitive dysfunction at each stage was also made. A similar retrospective
and record-based approach was used to document which patients had had
abnormalities of other "higher cerebral" functions, including dysphasia,
dyspraxia and visual agnosia. When such abnormalities were identified in
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the entire sporadic group (mean 7 months; median 4 (range 1 to 28) months).
There were 9 patients with cerebellar incoordination but no apparent
cognitive impairment at this stage. Theoretically patients with the Brownell-
Oppenheimer variant (of progressive cerebellar incoordination, vide supra)
should be included among these. Patients with such presentations are listed
separately in the CJD surveillance unit, and cross-referencing revealed 3
cases included in both lists, 3 cases of CJD with progressive cerebellar
incoordination not identified in this series (but all of whom had a "pure"
cerebellar disorder at presentation), and 6 patients identified here who were
not deemed to have suffered from this form of CJD (J. MacKenzie, personal
communication). While emphasising the inevitably subjective nature of such
classifications, these observations also indicate that this variant form of CJD
is rare (probably not accounting for more than 4% of sporadic cases). Finally,
bulbar dysfunction was identified in only 3 cases (2%) at this early stage.
As the disease progressed in this group of sporadic cases, multi-focal
cerebral dysfunction was the norm, and further sub-division on the basis of
the pattern of cerebral dysfunction was not feasible. Cognitive impairment
was probably universal, being not recorded in this series in only 2 cases
(present in 99%). The other clinical criteria used for classification (vide supra)
were identified frequently:
Myoclonus 122 cases 85%
Cortical blindness 75 cases 52%
Akinetic mutism 107 cases 75%
Pyramidal signs (Py) 88 cases 62%
Extra-pyramidal (Par) 74 cases 52%
Cerebellar (C) 122 cases 85%
(Py, Par or C 139 cases 97%)
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It is of note that primitive reflexes were noted in 83 cases (58%) and motor
dyspraxia was present in 79 cases (55%). Paratonic rigidity in isolation was
recorded in 55 cases (38%), but is likely to be an underestimate (due to its
misclassification in the pyramidal or extrapyramidal categories). There were
some differences in the frequency of these criteria between definite
(pathologically proven) and probable (electrophysiologically proven) cases
(Table 7), with myoclonus, cortical blindness and akinetic mutism all being
recorded more frequently in the latter group. However, this difference did not
reach statistical significance (Chi-squared = 5.256, df = 5, p = 0.3854). This
observation is of some importance in relation to the validity of clinical criteria
in epidemiological studies of CJD, and will be discussed later. Even in
advanced disease, features such as bulbar dysfunction, seizures and
respiratory depression remained unusual, with respective frequencies of 8%,
13% and 15%.
The disease durations of these cases are presented in figure 6. As noted
previously, the mean and median disease durations are 7 and 4 months
respectively. There is a suggestion that the distribution is bi-modal, with a tail
of patients succumbing after 12 months. A further small number of patients
are noted to have a disease duration in excess of 24 months. The relative
proportions of patients with long disease durations are:
> 12 months 14/139 10%
> 24 months 6/139 4%.
Table 8 is a summary of the clinical, pathological and molecular biological
data on these cases. In view of the previous observation of an inverse
relationship between disease duration and age of onset in sporadic CJD, a
younger mean age of onset might have been expected here. The mean age
of the group was 62 years (range 44 to 77, median 60), and comparison of
months) duration cases revealed no significant difference by Mann-Whitney
U (z - 1.7811, corrected for ties; p = 0.0749). During the course of illness,
there was nothing remarkable about the clinical features of these cases. The
first clinical features were studied in more detail, particularly as this might
have enabled the identification of long duration cases at the time of their
presentation. In fact the proportions of patients presenting with cognitive
impairment alone, cerebellar features alone, a combination of cognitive and
cerebellar disturbance, and cortical blindness were 40%, 30%, 10% and 5%
respectively. It will be recalled that these proportions are almost identical to
those noted for the sporadic group as a whole. Where it was performed, EEG
was diagnostic (showing periodic sharp wave complexes) in 33% of cases.
PRNP genome analysis was performed in 6 cases, and of these 5 were Met
homozygous at codon 129 and one was heterozygous. Neuropathological
examination always revealed diffuse spongiform change, and in 2 (out of 10
cases) anti-PrP positive amyloid plaques were noted. The significance of the
EEG, molecular biological and pathological features of this group will become
apparent later, but for the present there appears to be little that distinguishes
this group of patients from the entire group of patients with sporadic CJD
(apart from their longer duration of disease).
2.1.2 Investigations
EEG, liver function test, CSF, and CT/MRI data were gathered systematically
from patients in the study. The results are summarised in Table 9. In the case
of EEGs, strict inclusion criteria were used. Examples of recordings classified
as typical are shown in Figure 7. The two recordings shown in Figure 8 are
from the same patient (with pathologically confirmed CJD) and were
performed less than a week apart. There is a clear progression in the
appearances to become typical, emphasising the importance of repeating
recordings. The recording shown in Figure 9 although suggestive was
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classified as atypical. The danger of considering suggestive recordings as
typical is illustrated by the examples shown in Figure 10. The patient was
found to have ATD at autopsy. The proportion of cases with pathologically
confirmed CJD in which the EEG was typical was 35%. Correlation between
clinical features and EEG appearances was attempted. 48% of patients with
<12 months disease duration and 33% of patients with >12 months disease
duration had typical EEG appearances, but this observation was not
statistically significant (Chi square = 0.781 (with Yates' correction), df = 1, p =
0.3769). When myoclonus was present, EEG was positive in 49% of cases;
when myoclonus was absent, EEG was positive in 20% of cases (Table 10).
The total number of cases without myoclonus was small, and the result did
not reach statistical significance (Chi square = 3.457 (with Yates' correction),
df = 1, p = 0.0630).
Abnormalities of liver "function" have been alluded to previously, and this
systematic examination has confirmed this finding in almost half of all cases.
Overt liver failure was not present in any of the cases, however, and the
abnormalities usually amounted to a mild elevation of the hepatic enzymes.
Serial studies were performed infrequently, but the impression gained was
that the elevations were transient.178,179 Figure 11 is an illustrative example of
this phenomenon. At autopsy of this case, CJD was confirmed and the liver
was found to have fatty change.
The abnormalities in the CSF were usually elevations in protein content. In
this study, recordings above 0.4 grammes per litre were considered
abnormal. Although a value of 0.92 was noted in a single case, the elevations
were usually more modest. CSF examinations were rarely repeated, but in
one case values of 0.34 and 0.76 were recorded approximately a month
apart. At the second recording, however, 6225/mm3 red blood cells were
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present, making the interpretation difficult. A leucocyte response was never
found.
The finding of abnormal CT or MRI findings in almost 60% of cases was
surprising. Usually comments such as "mild atrophy" were present in reports.
Whether these interpretations were influenced by the clinical data provided is
unknown. Where scans were reviewed personally, a subjective impression of
cerebral atrophy was sometimes formed, but this was not validated by
comparison with age-matched controls. Patients with long duration disease
might be expected to show more pronounced cerebral atrophy, and in order
to investigate this the proportions of cases reported as abnormal in short and
long duration cases were identified. The respective values were 56% and
67%, a finding which was once more statistically insignificant (Chi square =
0.340 (with Yates' correction), df = 1, p = 0.5598). MRI abnormalities have
been reported in CJD. The extensive white matter degeneration reported by
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Uchino et al may be specific for the Japanese panencephalopathic variant
of CJD (vide supra). In reports from Western countries, high T2-signal lesions
in the basal ganglia have been described.181,182 In this study, three patients
with sporadic disease had similar findings. Clearly, the abnormality is not
universal in CJD, and it has been suggested that the finding may be specific
for cases of CJD with pronounced extra-pyamidal features.183 Of the three
patients here, one presented with Parkinsonian features, but the other two
had cognitive impairment alone. Of the latter, one patient did not exhibit any
extra-pyramidal features during the course of her illness.
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3.1 Familial CJD
In Table 11, clinical, electrophysiological and pathological data from cases of
familial CJD identified in the study are presented. In addition to the earlier
observations, on the younger age of disease onset and the longer disease
duration in these cases, there are several points of interest. The estimate for
familial CJD based on this study population is 8%. However, this is likely to
be an under-estimate as not all cases of familial CJD will be referred to this
unit, given its interest in sporadic disease. Furthermore, as referrals are
based on the clinical suspicion of CJD, familial cases (which tend to have
atypical clinical forms) will be referred less frequently. In fact, based on the
total number of cases which have been screened for PRNP mutations, the
best estimate for familial CJD is 16% (13 out of 81 screened cases, excluding
5 screened cases of iatrogenic CJD). It should be noted that the patients
bearing reference numbers 122 and 165 are from the same pedigree (first
cousins).
The clinical diagnosis of CJD tended to be made in cases with the codon 200
(Glu - Lys) mutation and also in cases with extra base pair insertions in the
octapeptide repeat region. Diagnostic EEGs were only obtained in cases with
these types of mutations. However, the suspicion of CJD must have been
sufficiently high for clinicians to have referred the cases in this study to the
unit in the first place. This point is particularly salient in relation to the point
mutations at codons 102 and 178. In both cases of FFI, bearing the codon
178 (Asp - Asn) mutation in association with Met at codon 129 of the mutated
allele, the referring Neurologists suspected CJD. Although insomnia was a
prodromal feature in both cases, dysautonomia was not marked, and the
presence of cognitive impairment, dyspraxia, chorea, myoclonus, cerebellar
incoordination and akinetic mutism (features present in both patients) would
have been consistent with CJD. The neuropathological examinations in both
55
cases, however, were conclusive. In case 145, which was found to carry the
codon 102 (Pro - Leu) mutation "diagnostic" of GSS, the clinical presentation
was entirely in keeping with CJD. Even on neuropathological examination,
the anti-PrP positive amyloid plaques (which were present, Figure 12a) fell
short of the large, multi-focal aggregates described in the literature. The
clinical phenotypes associated with this mutation appeared to vary from case
145 with an illness similar to CJD, to case 234 which resembled ATD (with
cognitive impairment but no evidence of cerebellar incoordination). The
mechanisms underlying this phenotypic variability are unknown. There was
insufficient data on codon 129 genotype in these cases to investigate the
effect of this site. There was a single case with a codon 117 (Ala - Val)
mutation. In this patient the phenotype was consistent with GSS, and not the
"telencephalic" variant (there being no pyramidal or extra-pyramidal signs).
The two cases bearing 144 base pair insertions in the octapeptide repeat
region were not related. Furthermore, the nucleotide sequence was different
in the two cases, and it seemed unlikely that they could have evolved from
one another. Intriguingly, the amino acids encoded by the extra base pairs
were identical in the two pedigrees, and this may have accounted for the
similarity in the variety of clinical diagnoses attached to affected members of
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the families through the years. The brother of case 173 was thought to
have died from Huntington's disease thirteen years previously. Re-evaluation
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of his neuropathology confirmed CJD.
The variable neuropathological findings in affected members of case 301's
pedigree have been mentioned.134,135 In his case, routine histochemistry
revealed no abnormalities, but staining with anti-PrP antibody revealed
punctate positivity (data courtesy of I. Janota, Institute of Psychiatry, The
Maudsley Hospital, London). In this pedigree, the allele bearing the extra
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base pair repeats always encoded Met at codon 129. Members of this
extensive pedigree whose normal allele also encoded Met (homozygous at
codon 129) had a younger age at death than members whose normal allele
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encoded Val at this site.
The issue of family history is important, and as seen in Table 11a positive
history was obtained in a large proportion of cases (11 of the 13 cases for
whom this information was available, or 85%). However, it is important to
emphasise that the family history rarely suggested CJD per se. More
frequently, vague references to disorders such as "Parkinson's disease",
"multiple sclerosis" and "motor neurone disease" in other family members
were made. In comparison, in the group of patients without PRNP mutations
the proportion of cases with positive family histories of neurodegeneration
was 26% (Chi square = 13.650 (with Yates' correction), df = 1, p = 0.0002).
Finally, in Table 12 the clinical characteristics of familial cases as a group
have been summarised, at presentation, early in the illness and during the
course of illness. In order to detect any differences in features between
sporadic and familial cases, Spearman rank correlation of the relative
frequencies of features at each stage has been performed. The data are
included in Appendix 4: for each characteristic the proportions of sporadic,
familial and, for a later analysis, iatrogenic cases manifesting this are
tabulated. Columns 1 to 3 represent the frequencies at presentation, columns
4 to 6 the frequencies early in the course and columns 7 to 9 frequencies
during the illness. According to the analysis, if there is a difference in the
clinical phenotypes of the two forms of CJD at any stage of illness, a non¬
significant p value would be recorded. Given the manner in which the
presence or absence of features was recorded for analysis, the relative
magnitude of type 1 errors (including features as present when absent) is
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likely to be greater than that of type 2 errors. The results of the analysis have
been summarised in Table 13. It appears that there is no difference in the
clinical characteristics between sporadic and familial cases referred to this
unit, at any point of the illness.
4.1 Iatrogenic CJD
The causation of CJD in the twelve cases of this type in this study was as
follows:
Cases 072, 025, 127, 160, 260, HGH
274, 279, 308 and 255
Case 029 HGnH
Cases 054 and 333 Dura mater grafts.
Clinical data was available on all cases except case 255. The dura mater
recipients presented at 44 and 46 years, and had disease durations of 5 and
11 months. Their clinical illnesses were similar to sporadic CJD. EEG was
typical in case 333, but not in case 054.
The clinical characteristics of the CJD cases who had received treatment with
HGH/HGnH, and for whom clinical data was available, is presented in Table
14. The striking feature is that almost all cases presented with cerebellar
incoordination, and that early in the course this abnormality was invariably
present. During the course of the illness, cognitive impairment was recorded
to a variable extent, and 4 of the 9 patients (44%) reportedly never had
features of this. Clearly, as these patients were not clinically monitored
throughout their illness for the development of cognitive deficits, this
observation needs to be interpreted with some caution. Nevertheless, 99% of
sporadic cases were reported to have cognitive impairment (using similar
58
methods of ascertainment) during their illness. The implication may be that
even when cognitive impairment develops in iatrogenic CJD via peripheral
routes of inoculation, it is subtle and/or qualitatively different.
In Table 15 rank correlation of clinical characteristics at various stages of the
disease has been performed between this group of patients and patients with
sporadic disease. During the early part of the illness, a statistically detectable
difference in clinical characteristics was present.
5.1 Non-CJD
A total of 41 cases with (eventually) pathologically confirmed non-CJD were
referred to the unit during the period of study. With one exception, the
diagnosis of CJD was entertained by the clinicians responsible for the
patients during their terminal illnesses. The neuropathological diagnoses in
these patients are presented in Table 16. The case of "spongiform
myelinopathy" was in a girl of 15 years who collapsed and died a few hours
later. Her case was referred to the unit by the OPCS, and further enquiries
including examination of the post mortem report revealed this to be a case of
sudden death associated with white matter disease which was unlikely to be
confused with CJD clinically. This case and four others (with diagnoses of
ATD (3) and ATD with multi-infarct disease (1), in whom clinical data was
unavailable) were excluded from further analyses. As can be seen, the
majority of patients without CJD had ATD either in isolation or in association
with another neurodegenerative process (58%; 23/40).
The mean age of presentation for the group without CJD as a whole was 66
years (median 65; range 45-85). The mean disease duration in these patients
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was 31 months (median 16; range 1-151). When compared with the sporadic
CJD group, the disease duration in these cases was significantly longer
(Mann Whitney U, z (corrected for ties) - 4.8675, p < 0.0001).
In Tables 17 to 19, the clinical characteristics at presentation, during early
disease and during the course of illness in pathologically confirmed non-CJD
cases (n = 36) have been compared with CJD cases with sporadic (n = 143)
and familial (n = 14) disease. The CJD cases were considered together as
information on PRNP genotype would not normally be available at the time
the clinical diagnosis is made, and as noted the clinical characteristics of
sporadic and familial CJD cases do not differ. As well as estimating the
sensitivity and specificity of individual clinical characteristics, positive and
negative predictive values have been calculated.184 It has to be stressed that
these calculations are based on a large number of CJD cases, but a very
small number of non-CJD cases. The latter group was also non-
homogeneous, and the relative importance attached to each individual
clinical characteristic would have been heavily influenced by the frequency
with which they occured in this "control" population. The positive predictive
value in this context is probably meaningless, as the population prevalence of
CJD is so low. In other words, even if a particular clinical characteristic had a
high positive predictive value here, when applied to the whole population the
number of false positives picked up on the basis of this sign would far
outnumber the number of true CJD cases.
Nevertheless, there are several interesting points that emerge:
1. At presentation, the only clinical features that appear to have
any sensitivity are cerebellar incoordination and the various aspects of
cognitive impairment. However, all the features have high specificities
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at this stage, with "disorientation" having the (comparatively) lowest
value of 0.6944.
2. During early disease, incoordination remains the most sensitive
marker of CJD, and its specificity remains high. All the aspects of
cognitive dysfunction remain sensitive with fair degrees of
specificity. Interestingly, motor dyspraxia emerges as a feature
with moderate sensitivity, as do myoclonus and cortical blindness.
However, the latter two have superior specificities.
3. During the course of illness, most of the diagnostic criteria emerge
with high sensitivities. In addition to the various markers of cognitive
dysfunction, myoclonus, cerebellar incoordination, akinetic mutism,
pyramidal dysfunction and cortical blindness all have sensitivities
greater than 0.5. Muscle wasting is an exception, with a sensitivity of
0.1656. At this stage, primitive reflexes and motor dyspraxia are also
found to have high sensitivities. The specificities of the traditional
diagnostic criteria were high with the exception of markers of cognitive
dysfunction (due to the high prevalence of "dementia" in the non-CJD
group) and, surprisingly, myoclonus. ATD with myoclonus is an
important differential diagnosis in CJD,47 and of the 19 cases with ATD
in the non-CJD group for whom clinical data was available, this
characteristic was present in 11. The specificities of primitive
reflexes and motor dyspraxia were more modest, but paratonic
rigidity emerged as a feature with an impressive specificity of
0.7222 (sensitivity = 0.3949).
As indicated previously, at the time a patient is suspected of having CJD and
the clinical signs are elicited, the eventual outcome is unknown. The exact
diagnosis in those patients who either recover or whose condition does not
progress (designated other# in this study) is unknown. The group also
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includes a small number of patients who died (without post mortem
examinations), but the last available data on these subjects suggest that CJD
is untenable. Not only is the group likely to be heterogeneous, but CJD
cannot be ruled out for certain. It is because of the latter factor in particular
that this group has been excluded from the analysis of clinical features
between CJD and non-CJD cases. However, in order to validate the
observations regarding clinical signs (at the time a case is initially assessed),
a comparison between the relative frequencies of these signs at presentation,
early in the course and during the illness has been made between other and
other# cases.
At presentation, there were no differences between the two groups (Table
20). Early in the illness, pyramidal dysfunction, cortical blindness and
incontinence were observed more frequently in the pathologically-confirmed
non-CJD group (Table 21). During the course of illness, these features no
longer remained significantly different, but facial weakness, akinetic mutism
and (not surprisingly) respiratory depression were commoner in the "other"
group (Table 22). These results imply that the conclusions drawn about the
relative sensitivities and specificities of the various clinical signs above are
valid when considering patients with suspect CJD during life.
6.1 Clinico-pathological correlation
The information was collated as described in the Methods section, and is
included as Appendix 5. Data from 73 sporadic cases of CJD was available
for analysis. The results from comparing clinical and pathological features in
each area of brain in these cases are presented in Table 23. Overall, the
basal ganglia were the most likely area of brain to show sponge (93% of
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cases examined), followed by the cerebellum (92%), the temporal lobes
(86%), the occipital lobe (81%),and the frontal and parietal regions (66% in
both). The brainstem was the area of brain least likely to reveal spongiform
change, this being present in 12% of cases only. In all areas of brain except
the frontal lobes, there was no significant correlation between clinical
features and sponge distribution. This poor correlation could be attributed in
most regions to the lack of clinical features accompanying spongiform
change. For example, of the 68 cases showing sponge in the basal ganglia,
38 had no clinical features of basal ganglia dysfunction. Approximately a third
and a quarter respectively of cases with clinical signs of parietal and frontal
lobe dysfunction failed to show sponge in these regions. It is important to
stress that the assessment of pathology did not include other features such
as neuronal loss or astrocytosis. The descriptive pathology reports did not
enable quantification of the spongiform change either.
Eleven cases contained anti-PrP positive amyloid plaques. This
approximated to 15% of sporadic CJD cases in this unselected series.
Clinical, pathological and molecular biological data on these cases are
presented in Table 24. The mean disease duration in this group was 11
months, but would have been influenced extremely by the single case with a
duration of 62 months. The median disease duration was in contrast 4
months, which was identical to the median disease duration of the sporadic
group as a whole. Analysis of the presenting characteristics of these cases
revealed that 55% had a purely cerebellar presentation and that 45%
presented with some aspect of cognitive dysfunction alone. When compared
with the presenting features of the rest of the sporadic group, this observation
did not reach statistical significance (Chi squared = 5.030, df = 4, p =
0.2843). Characteristic EEG findings were present in only 2 of the 10 cases
for whom this data was available, but comparison with the rest of the sporadic
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group did not yield a statistically significant result (Chi squared, with Yates'
correction = 1.896, df = 1, p = 0.1685). Of the four cases for whom molecular
biological data was available, two were MV, one was W and one was MM.
Finally, a single case in this sub-group had co-existing ATD. This was a 75
year-old female with an estimated disease duration of 5 months, but her
family members had been aware of memory lapses and odd behaviours
which were mild and not rapidly progressive for almost 18 months prior to the
onset of her "acute" and terminal decline. The clinical course of her CJD was
unremarkable, and her EEG was characteristic. She was Met homozygous at
codon 129 of PRNP ORF. In contrast to previous reports,185,168 this patient did
not have a "long" duration of disease, and when her history was carefully
reviewed there was a distinct change in her cognitive and neurological
systems with the presumed onset of CJD. The coincidence of ATD with CJD
is difficult to gauge based on this series, but the roughly 1% rate is
compatible with chance concurrence of the two disorders.
7.1 Molecular biology
Data on familial cases (bearing mutations of the PRNP ORF) has already
been presented. For the familial group as a whole, there was no significant
difference in age of onset or disease duration when cases which were Met
homozygous at codon 129 (n = 6) were compared with cases which were
heterozygous at this site (n = 3) (Table 25).
Excluding the familial cases, PRNP ORF codon 129 genotype data was





In sporadic CJD cases, 84% were Met homozygous; in non-CJD cases 50%
were Met homozygous (Figure 13). The distribution of Met and Val at this site
of common polymorphism is different between sporadic CJD and non-CJD
cases (Chi squared = 8.527, df = 2, p = 0.0141). In an alternative analysis of
some of these data, we found that both Met and Val homozygosity were
significantly associated with the development of sporadic CJD (the relative
risks of Met/Met: Val/Val : Met/Val being 11:4: 1).102 Here, this finding was
not reproduced. In the published work, the polymorphic status of the definite
and probable cases was compared with that of the normal Caucasian
population. (The comparison of "possible" and "other" cases with the normal
population revealed no significant difference.) It should also be noted that in
the only other two population-based analyses of codon 129 status in sporadic
CJD, Met homozygosity alone was implicated as a risk factor.101,200 The
explanation for this apparent discrepancy is unclear, but may be due to the
infrequency of Val homozygous sporadic CJD cases and the relatively lower
level of risk that this genotype confers compared with Met homozygosity.
The comparison of ages of disease onset and disease durations in sporadic
CJD cases between Met/Met, Met/Val and Val/Val cases is presented in
Table 26. There appears to be no difference in these parameters depending
on genotype.
The clinical and pathological features of sporadic cases encoding Met/Val or
Val/Val at position 129 are summarised in Table 27. In this group of patients,
cerebellar dysfunction as a presenting feature was commoner when
compared with the presenting features of patients who were Met homozygous
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at this site (Figure 14; Chi squared = 15.689, df = 4, p = 0.0035).
Furthermore, EEGs in these patients were rarely diagnostic (Chi squared,
with Yates' correction = 10.254, df = 1, p = 0.0014). Neuropathological
examination in these cases was more likely to reveal anti-PrP positive
amyloid plaques (Figure 15; Chi squared, with Yates' correction = 4.078, df =
1, p = 0.0434). In summary, sporadic cases of CJD that are either
heterozygous or Val homozygous with respect to the amino acids encoded at
codon 129 of PRNP ORF, have identical ages of disease onset and durations
of disease to Met homozygous cases. Flowever, they tend to present more
frequently with cerebellar dysfunction, rarely manifest typical EEG
appearances and are characterised more frequently at neuropathological
examination by anti-PrP positive plaques. It should be stressed that these
amyloid plaques are quite different from the multicentric lesions
"characteristic" of GSS. In these sporadic cases, the lesions are distinctive
unicentric deposits (Figure 12b).112,113
In the five cases of iatrogenic CJD for whom codon 129 genotype data was
available, two HGH recipients were Val homozygous, one HGH recipient was
heterozygous, the HGnH recipient was Val homozygous and one of the dura
mater graft recipients was Met homozygous at this site.
7.1.1 Counselling data
In Table 28, requests for the results from PRNP genome analysis by relatives
have been noted. Overall, 73% of relatives expressed a wish to know the
result. Requests did not appear to be influenced by the presence of a family
history of neurodegeneration (p = 0.6273), whether the respondent was a first
degree relative (p = 0.3069), or the family's level of education (p = 0.3354).
(All calculations were performed by Chi square test, assuming Yates'
correction and df = 1.)
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1.1 The study design
In this study, an attempt has been made to analyse the clinical features of CJD
systematically. Bias in case ascertainment has been minimised by including
consecutive definite and probable cases of CJD referred to the UK national
surveillance unit over a defined period (1990-1994). The period of study
coincided with an unprecedented interest in the spongiform encephalopathies in
this country.186 Also, as indicated previously, cases are referred to the unit by a
wide variety of sources, including neurologists, general physicians, geriatricians,
psychiatrists and electrophysiologists. Neuropathologists and the Office of
Population, Census and Statistics act as checks after death, so that there is
virtually complete ascertainment of cases. The neurology and neuropathology
communities in the UK are relatively small, and there are close links between
members. There are regular contributions to the meetings of both groups from
members of the surveillance unit. The work of the unit, therefore, has a high
profile, and it is likely that most, if not all, identified cases of CJD are being
referred. There is, however, a very real concern that cases of CJD with atypical
presentations and courses are being missed. Clearly this must be occurring (if at
all) in a systematic way in all countries where surveillance is taking place, as the
epidemiological and clinical features of CJD in surveys worldwide are so
consistent. The dependence on the Masters' criteria in particular may lead to the
systematic under-ascertainment of cases of CJD not fulfilling these. There is
some evidence in the present study that this is in fact unlikely to be the case.
Firstly, cases designated "other" and "other#" in the study were suspected as
having CJD at the time of referral; the "other" patients had an alternative
neuropathological diagnosis established post mortem, and were clinically
indistinguishable from "other#" patients (in whom the final diagnosis was
unknown). It is likely that this entire group of patients, who do not fulfil criteria for
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inclusion in the study as probable or possible CJD cases, do not in fact have the
disease. If this group of patients who after all were referred by experienced
neurologists as suspect CJD do not have it, it seems unlikely that CJD cases are
masquerading with even more obscure presentations. Secondly, the
identification of atypical variants of CJD such as FFI and (since the completion
of the work presented here) vCJD by the unit argues strongly against the
contention that the criteria for inclusion or exclusion in use are overly rigid.
It is conceivable that there are cases of CJD within the group of patients
classified as "possible". These cases were not included in this study because
their final status was uncertain (they could also have had a neurodegenerative
process other than CJD). It is arguable that an unusual phenotype of CJD (not
associated with periodic sharp wave complexes on EEG) has been missed by
this approach. As will be argued later, the only reliable means of confirming or
refuting this suggestion is by the systematic neuropathological examination at
autopsy of all patients with neurodegeneration. However, it is unlikely that
numerically these cases constitute a large group. The incidence of CJD during
the period of this study based on the study criteria (0.773/million/year) is well
within worldwide norms. Even if one assumes an annual incidence of
1.0/million/year, only a dozen cases have been omitted annually from the study,
and not all of them would have had this putative phenotype. On balance,
therefore, not only is it likely that virtually all suspected cases of CJD in the UK
between 1990 and 1994 have been referred to the unit, but that the patients
studied here constitute the bulk of the real cases.
The clinical data in the study has been collected by four experienced clinical
neurologists, either by personal history-taking and examination, or by the careful
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perusal of case sheets and investigations. The data was then entered into a
standardised proforma. These measures have ensured a high degree of
uniformity in the quality of the assimilated data. There is indirect support for this
contention from the numbers of cases allocated to the various categories
(definite, probable, possible and other) in the survey. Over the entire study
period, the relative proportions in these categories have remained remarkably
stable despite the involvement of different investigators (R. Will, personal
communication). A similar observation was made during the current study: it was
impossible to differentiate between the respective researchers on the basis of
data available on individual patients.
Inevitably, there will be disagreement between observers on the presence or
absence of (particularly subtle) clinical signs.187 The estimation of this (kappa
statistic) for the individual clinical features is beyond the scope of this study.
Nevertheless, as considerable weight has been given here to the prevalence of
cardinal clinical features, this deficiency has to be acknowleged. The
neuropathological and molecular biological techniques have been performed
and reported by highly experienced scientists. In comparison with the clinical
data, the degree of uncertainty in these observations is low. The main caveat to
this statement applies with respect to those cases which have been examined
neuropathologically at other centres. However, it has been the policy of the unit
to evaluate such cases independently, by the re-examination of wet tissue or by
obtaining fresh sections from representative blocks. In all such cases, the report
issued locally has been considered in preference.
The method for recording the presence or absence of clinical features in the
current study may have over-estimated their prevalence. The use of a bi-nomial
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variable would have encouraged the tendency to indicate as "present", when a
feature was suspected or queried. In practice, this decision was rarely based on
a single observation. For example, if a patient was suspected of being cortically
blind, corroborative evidence of visual disturbance was sought from the history.
Given that clinical data was gathered at one point in time (which may have been
days, weeks or even months before death), and the availability of follow-up data
was haphazard, the occurrence of some clinical features may have been
underestimated. It is difficult to ascertain whether the presence of certain
features was consistently underestimated by this mechanism: signs of bulbar
dysfunction, for example, which probably occurs (if at all) late in the disease may
have been ignored. In clinical practice too there is a tendency to be less
clinically inquisitive, as it becomes clear that one is dealing with a progressive
and untreatable condition, and the emphasis turns towards terminal care.
Data on investigation results was far from comprehensive. This is inevitable
given the wide variety of sources from which patients were referred.
Investigations such as EEGs were rarely repeated. The normal ranges for liver
enzymes and CSF protein content were not always available. Given the design
of the surveillance project, and the heavy reliance on the goodwill of referring
clinicians, it is difficult to know how best to overcome these deficiencies. Given
the nature of the disease, the ethics of repeating blood or CSF examinations for
purely research purposes are dubious, especially when the patient is perceived
to be in pain as a consequence. Despite these reservations, sufficient data on
these investigations has been generated to enable the drawing of some broad
conclusions.
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In one part of the study, different stages of the disease process have been
identified to aid classification. This is clearly a highly subjective exercise, there
being no definite demarcations between "at presentation", "early course" and
"during illness". Despite this arbitrariness, it has aided clinical speciation
particularly at presentation. From this standpoint, it has been possible to make
correlations with patients' neuropathological and molecular biological data. The
present author had little difficulty in dividing the clinical information available in
the proforma into these categories. It would be interesting to compare these
numbers with those obtained by another clinician faced with the same data. If a
degree of uniformity emerges, it will strengthen the clinical utility of this method
of analysing the clinical presentation of CJD cases.
2.1 Sporadic CJD
2.1.1 Disease onset
The estimate for the median age of onset (based on review of the clinical
history) in the sporadic CJD group was 65 years. This value is slightly greater,
but consistent with recent large epidemiological surveys.40,41 The apparent bi-
modal distribution in the ages of onset (Figure 4), if a real observation, and not
due to a chance phenomenon related to the relatively small number of cases
studied, is worthy of investigation. It may, for example, indicate different
mechanisms of disease acquisition in the population: the "younger" group
developing the disease after a defined incubation period after exposure to the
causative agent early in life, and the "older" group succumbing to an abiotrophic
process with the passage of time. In the latter scenario, and indeed according to
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the prion model, one would expect a progressive increase in the prevalence of
sporadic CJD with increasing age.96 This has not been noted in the present
study. Inevitably, the accusation will be levelled that case ascertainment in the
elderly is poor, but in unselective post-mortem studies there is little support for
the suggestion that significant numbers of CJD cases in the elderly are being
missed.188,189'190 Furthermore, the design of the current surveillance study, its
reliance on a wide variety of sources of referral and the unique clinical
characteristics of the disorder all militate against this bias. Analysis of the
clinical characteristics of elderly cases shows no difference from the group as a
whole (data not shown).
The age of disease onset and indeed disease duration in the sporadic group
were not associated with the common polymorphism at codon 129 (Table 26). It
has to be noted however that the number of cases that were heterozygous or Val
homozygous was small. The APOE genotype in this group of patients has not
been studied. It is of note that the earlier French experience of the influence of
the e2 genotype on (longer) disease duration142 has not been reproduced.143 It is
conceivable, as explained in the introduction, that the influence of this gene is
limited to those cases of sporadic CJD exhibiting amyloid plaques.
2.1.2 Disease duration
There was an apparent correlation between age of disease onset and disease
duration in sporadic CJD cases (Figure 5). This is not a startling or unexpected
observation, and probably merely reflects the reduced capacity of the elderly to
withstand the vicissitudes of a progressive dementing process. At a simplistic
level, the prion hypothesis may be questioned on the basis of this observation. If
the capacity for the development of CJD and its rate of progression are
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governed by the degree of homology of interacting PrP molecules, should not a
more rapid disease process ensue in those developing disease at a younger
age?
As review of previous studies has shown, the apparent long duration of disease
in young cases is partly attributable to the inclusion of familial cases in these
series. This supposition is strongly supported in this study: familial cases
presented on average 10 years younger (median = 55) and had a disease
duration that was twice as long (median = 8 months, compared with a median
disease duration = 4 months in the sporadic group). From the perspective of the
prion theory, it may be argued that the degree of homology between PrP
molecules available for interaction in familial disease is reduced, in that the
PRNP ORF mutations are usually limited to a single allele. The presence of the
mutation may still promote the conversion of PrPc to PrPSc more readily, than
that which occurs by chance in sporadic cases. In sporadic cases, however,
once the conversion has taken place, the process can propagate more easily
given the total homology between interacting species.
Fourteen per cent of the sporadic patients had disease durations greater than a
year. Detailed analysis of the clinical, neuropathological and molecular
biological features of these patients revealed nothing remarkable (apart from
their disease durations). As indicated previously, and in contrast, some CJD
cases have a rapidly progressive course, with an onset and evolution resembling
stroke.167 The observation that a single neurodegenerative process can exhibit
such diverse characteristics is clinically fascinating, but it may simply be a
reflection of the extremes of biological behaviour of this disorder in man.
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2.1.3 Clinical characteristics
The method of study employed has enabled the classification of sporadic cases
into phenotypic groups. The reliability of such techniques has already been
questioned, but it is of note that the proportions of cases presenting in the
current study with cognitive dysfunction in isolation, cerebellar dysfunction in
isolation, combined cognitive and cerebellar dysfunction, and cortical blindness
(40%, 30%, 10% and 10% respectively) are in keeping with the presenting
features of cases in earlier worldwide surveys.42,40,41 The roughly similar
proportions of patients manifesting various clinical signs in Brown's 1994 study
(in which all cases were experimentally transmitted)41 and the current series is
also notable (Tables 3 and 6). These observations lend considerable validity to
the surveillance project in general and the current study in particular: the cases
being studied constitute a group of patients with clinical features identical to
those described in previous epidemiological studies and are representative of
cases of transmissible human spongiform encephalopathy as conventionally
understood.
The proportion of cases with Parkinsonian features (52%) is higher than that
estimated by Will and Matthews (3%),42 but in line with the estimates in Brown's
series (56%,67%).40,41 Will and Matthews classified rigidity in isolation as a
pyramidal feature, whereas here increased tone throughout the range of
movement of a joint (of "cogwheel" or "leadpipe" type) has been considered as a
Parkinsonian feature. Parkinsonism is a difficult feature to establish in CJD as
patients are not mobile and do not speak or write. Although it is an unusual
presenting feature of CJD, as the pathological examinations attest, involvement
of the extra-pyramidal system in CJD is not unusual. In contrast with the earlier
studies, the presence of paratonic rigidity (gegenhalten) has been classified
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separately, and recorded during the course of illness in 38%. Once again, it is
unusual to detect this phenomenon early in the disease, but with disease
progression (and presumed widespread cerebral degeneration) it emerges in a
high proportion of cases. As indicated, it is likely that this phenomenon of
increased tone has been misclassified as a pyramidal or extrapyramidal sign in a
number of cases, making the current value an under-estimate.
The comparison with a pathologically-confirmed group of non-CJD cases has
enabled closer scrutiny of the likelihood of the presence of various clinical
features predicting CJD. In general, the Masters' criteria38 emerged with high
sensitivities, but perhaps this is unsurprising in that the same criteria were used
in case selection. (This criticism can be levelled at all large epidemiological and
clinical surveys of CJD worldwide.) "Muscle wasting" stands alone among the
criteria in having poor sensitivity for the diagnosis of CJD, and lends support to
the contention that on the whole cases previously described as "amyotrophic
CJD" were patients with fronto-temporal dementia and motor neurone disease.
Comparison of this pathologically confirmed group of non-CJD patients with a
group of patients classified on the basis of the criteria as non-CJD but who have
either improved or not succumbed to their neurodegeneration, revealed that the
relative frequencies of diagnostic clinical features did not differ between these
groups. The validity of the comparison lies in the fact that all the cases were
referred to the unit as suspect cases of CJD. Therefore, the sensitivity and
specificity of each sign can be used to gauge just how likely the presence or
absence of this clinical feature makes the diagnosis of CJD likely, in a patient
being referred to a national centre with this diagnosis queried.
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The EEG data are a further point of interest. Again, its inclusion in the Masters'
criteria will lead to an inevitable over-estimation of its diagnostic value. In the
pathologically confirmed group, in whom this data was available, characteristic
appearances (by this study's criteria) were noted in 35%. This is likely to be an
underestimate of the total number of cases of CJD that have typical EEG
findings, in that probable cases may not have come for autopsy as readily as
those cases of suspect CJD in whom the diagnosis could not be established
during life. In contrast to Will and Matthews' data,42 there was no significant
tendency for EEGs to be uncharacteristic in long duration disease. There was a
suggestion that the EEG was likely to be negative in the absence of myoclonus
(Table 10), but the result was not statistically significant. It is of note that the
frequency of some clinical signs (cortical blindness, akinetic mutism,
Parkinsonian features and myoclonus) was higher in the electrophysiologically
confirmed group, than in the definite cases. The result did not reach statistical
significance, but does suggest that a proportion of cases may not develop
characteristic signs or EEG appearances. The over-reliance on the Masters'
criteria (and especially electroencephalography) may consequently lead to the
under-estimation of CJD cases. This observation has serious implications for the
surveillance of CJD. If humans were to become susceptible to the agent causing
spongiform encephalopathy via novel modes of inoculation, unusual and atypical
disease phenotypes might arise. These in turn might be expected to manifest
atypical EEG appearances.161 The recent experience with vCJD is perhaps an
illustrative example.162 An over-rigid adherence to the Masters' criteria would
lead to these cases being ignored. Perhaps the only certain means of avoiding
this would be to perform neuropathological examinations of the central nervous
system following autopsy in all cases of undiagnosed neurodegeneration during
life. A policy such as this will have important implications on clinicians' and
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neuropathologists' time, and neuropathological resources. This approach will
have the useful spin-off of generating an enormous amount of clinical and
neuropathological data on neurodegenerative processes in general.
At present, nevertheless, EEG remains the most useful diagnostic test in CJD.
Contrary to Nevin et ats early observations,20 this test has a high specificity (it
being rarely "positive" in an appropriate setting in conditions other than CJD).
Certain clinical features and phenotypes were confirmed as being rare in CJD.
No cases of panencephalopathic CJD were identified. The comparative
differences in the reported occurrence of this form of CJD between Japanese
and Western series is unexplained. The Brownell-Oppenheimer variant with
progressive cerebellar ataxia was also unusual, not accounting for more than 4%
of sporadic cases. The relatively low prevalence of bulbar dysfunction and
respiratory depression even in the advanced stages of CJD has been indicated,
and possible explanations suggested. It is unlikely that a similar problem with
ascertainment would apply to seizures (especially when generalised), and the
reported (low) frequency of 13% is likely to be accurate. A proportion of cases
may have received treatment with agents such as Clonazepam or Valproate for
myoclonus, which may have suppressed seizure activity. It is worth bearing in
mind that PrP null mice have demonstrated pro-epileptogenic
electrophysiological abnormalities, implying a gain of function role for this
protein.146 In disease states, such as CJD, it is argued that such abnormalities
will re-emerge. It is, therefore, slightly surprising that seizures are not more
commonly encountered in CJD.
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3.1 Differential diagnosis
The main differential diagnosis in the non-CJD group was ATD, accounting for
58% of cases in this group. In those cases of pathologically confirmed ATD for
whom clinical data was available, a high proportion (58%) had myoclonus. The
variety of other conditions in the non-CJD group was huge, and appeared to
encompass virtually the entire spectrum of adult neurodegenerative processes
(Table 16). The group as a whole had a disease duration roughly four times
longer than in patients with CJD (median = 16 months), and this was perhaps
the most useful discriminator. A single patient in this series had co-incident CJD
and ATD. This association has been described previously, and probably
represents a chance occurrence. Data gathered retrospectively from the
patient's record could be used to identify the onset of rapidly progressive
neurodegeneration (presumably CJD) on a background of subtle and slow
cognitive decline.
4.1 Familial CJD
Although the estimate for the proportion of cases of CJD that was inherited
based on large scale epidemiological studies was around 6%,44,36 a true figure
could only be arrived at by the systematic screening for all PRNP ORF mutations
in an unselected, large population of CJD patients. This was achieved in the
current study, and the estimate of 16% is in agreement with the experience in
France.101 The relatively younger age of onset and the longer disease duration in
these cases have been alluded to.
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A significantly greater proportion of familial cases (85%) was found to have a
family history of neurodegeneration. Although it could be argued that knowledge
of the PRNP genome analysis may have influenced the interpretation of the
family history, it should be recalled that this information was on the whole
collected prospectively (and before the molecular biological data became
available). Furthermore, the family history recorded rarely implicated CJD by
name, and more often referred to commoner neurodegenerative processes such
as Parkinson's disease. The estimate for family history of neurodegeneration in
cases without PRNP mutations (26%) was based on records of similar diagnoses
in first degree family members. This observation has important implications for
the assessment of family risk in individuals with CJD. The presence of a positive
family history of neurodegeneration clearly increases the likelihood of an
inherited form of CJD (relative risk = 3.24; 95% confidence interval = 2.02 -
5.17).
A wide spectrum of disease-associated mutations was recognised in the study
(Table 11). One of the pedigrees was found to have a novel 144 base pair
insertion in the octapeptide repeat region, and has been reported.90 As
mentioned, although the unusual disease phenotype of FFI has been stressed in
the literature, both cases identified here were suspected of having CJD by their
referring clinicians. The mutations described in association with GSS in the
literature were found to have highly variable clinical phenotypes. At one end of
the spectrum cases had clinical courses not dissimilar to CJD, while at the other
cases resembled ATD. There was insufficient data on codon 129 genotype to
draw any conclusions about the influence of this polymorphism on disease
phenotype.
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The case associated with the codon 117 mutation had a GSS-like disease
phenotype. A recent case report of an individual with the same mutation is of
interest: the clinical and pathological phenotypes of this case were also those of
GSS and not the "telencephalic" variant.191 In the recently reported case, as in all
reported cases of codon 117-associated CJD, Val was encoded by codon 129 of
the disease-bearing allele. In contrast to the mutation at codon 178,106
phenotypic variability in association with this mutation does not appear to be
determined by the polymorphism at codon 129. The polymorphic status of the
normal allele could be responsible, but this seems unlikely on the basis of the
relative homogeneity of clinical features in affected subjects from large
pedigrees. The other possibility is that there are further sites of genetic influence
on pathogenesis, as suggested in mink192 and mice.193 Clearly, further studies on
the pedigree of case 309 are warranted in order to examine these issues.
In contrast with the work of Poulter and colleagues,95 it was not possible to show
any effect on age of onset or disease duration of the pooled familial CJD cases
of the codon 129 polymorphism (Table 25). The explanation for this discrepancy
is not clear, but may be due to the effect of this site either being limited to certain
mutations or being identifiable within pedigrees only. It should also be noted that
the data available in the current study is limited to only nine subjects. If the
results of larger series confirm the lack of influence of this site on disease
characteristics, this would not necessarily bring into question the concept of
interacting PrP molecules as a key pathogenic mechanism. PrP molecules
derived from mutated alleles may have more crucial structural characteristics
which facilitate homologous interactions.
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The pooled data on clinical features of familial cases failed to show any
differences at presentation, early in the course or during the illness when
compared with the sporadic group. This analysis does of course ignore the fact
that in individual cases the suspicion of an inherited form of CJD may be raised
by certain clinical features, such as insomnia in FFI. Nevertheless, it appears
that it is untenable to base a diagnosis of inherited CJD on clinical features
alone and without PRNP genome analysis. It was equally difficult to predict the
type of PRNP ORF mutation based on the clinical phenotype. The typical CJD-
like illnesses identified in association with the codon 200 mutation and in those
cases carrying extra base pair insertions in the octapeptide repeat region were
exceptions. The second case of FFI was not recognised clinically but the
pathological findings were diagnostic (prior to the availability of the molecular
biological data).
Recent studies on familial cases of progressive subcortical gliosis have revealed
anti-PrP positive reactions, and linkage with chromosome 17 markers.194
Examination of the PRNP ORF revealed no mutations. The place of this entity
(which can also present sporadically) in the spectrum of human transmissible
spongiform encephalopathies is uncertain, but if transmissibility is achieved and
PrP is demonstrable on Western immunoblotting195 there will be a pressing need




The clinical characteristics of nine cases of CJD acquired following inoculation
of the agent outside the central nervous system were available for study. In
keeping with experience elsewhere, these patients presented with or manifested
early on features of cerebellar incoordination. Cognitive impairment was not
recorded in just over half of the patients. The validity of the clinical staging is
supported by the demonstration of a statistically significant difference in
characteristics between these cases and sporadic cases in the early part of
illness by Spearman rank correlation. (The difference in characteristics at
presentation also approached significance.)
The median disease duration of the iatrogenic cases was similar to that of the
sporadic group. From the point of view of the prion theory this is not a surprising
observation: the recipient's PrP molecules will have no difficulty interacting with
the PrP molecules in the inoculum (of human pituitary extract). The extent to
which homology at codon 129 (between recipient and inoculum) needs to be
satisfied for this interaction is unknown. Although the numbers were too small for
statistical analysis, out of the five iatrogenic cases for whom molecular biological
data was available four were homozygous at codon 129. Interestingly, all three
cases with agent inoculation outside the central nervous system and who were
homozygous (the fourth was heterozygous) encoded Val at codon 129. As
discussed in the introduction, pooled data has confirmed the increased
prevalence of Val homozygosity in patients who have developed iatrogenic CJD
after receiving human pituitary-derived hormones.100 Whether this is revealing
something fundamental about prion biology or represents a chance phenomenon
is currently unknown. One attractive hypothesis is that "matching" (with respect
to the amino acids encoded at codon 129) between recipient and inoculated PrP
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molecules may have led to the currently recognised cases. The human pituitary-
derived HGH and HGnH were, however, obtained from pooled supplies and the
molecular structure of the infectious particle(s) will never be known.
The observation regarding the short disease duration in iatrogenic cases is also
relevant in terms of our appreciation of their clinical characteristics. Although
recent descriptions of "peripherally inoculated" iatrogenic CJD cases have
referred to a "kuru-like" illness, closer scrutiny of descriptions of kuru and
analysis of the clinical characteristics of patients in series such as this reveal
important distinctions. The disease duration of kuru in Hornabrook's experience
was 12-18 months.29 Also, myoclonus is not described in kuru patients, but was
present in 7/9 "peripherally inoculated" cases studied here. The prominence of
cerebellar features, the early lack of insight and the late development of
dementia are features in common, and may (as is commonly suggested) imply a
dependence of the clinical features on the route of inoculation. Nevertheless, the
likening of illness in these cases to kuru is simplistic and probably inaccurate.
6.1 A comprehensive classification, and new diagnostic techniques?
6.1.1 Classification
Based on the foregoing, the human transmissible spongiform encephalopathies
can be summarised as follows:
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1. Sporadic CJD: "Classical"- presenting with cognitive dysfunction alone (40%)
presenting with cerebellar dysfunction alone (30%)
presenting with cognitive and cerebellar dysfunction (10%)
other presenting feature (10%)
Heidenhain variant - presenting with occipital blindness (10%)
Brownell-Oppenheimer variant - progressive cerebellar syndrome (rare)
Panencephalopathic - (rare)
2. Familial CJD: Phenotypes linked with 22 separate PRNP open reading frame mutations




Familial CJD with spastic paraparesis
Phenotype resembling Alzheimer's disease
But, considerable overlap and phenotypes not specific to mutations
3. Iatrogenic CJD: Central inoculation - resembles sporadic CJD
Peripheral inoculation - progressive cerebellar syndrome
4. Kuru
The classification is a clinical one, and may require revision on the basis of
future developments in neuropathology and/or molecular biology. The nosology
of entities such as vCJD, progressive subcortical gliosis and Alpers' disease
(vide infra) is not established, but arguments can be put forward for the inclusion
of each of them as a human spongiform encephalopathy. (Transmissibility has
not been unequivocally established for any of these conditions, to date.) In time,
therefore, the classification may require expansion.
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6.1.2 Novel "diagnostic" techniques
The absence of a true diagnostic test in CJD has been pointed out. The results
of investigations performed at the referring centres on the cases included for
study here (Table 9) were compatible with results reported elsewhere. The
results from the examination of CSF for the 14-3-3 brain protein of cases is not
reported in this study, but a systematic survey of cases versus non-cases
referred to the UK surveillance unit revealed that the specificity of this technique
was low.164 The German surveillance group has found the examination of CSF
for not only this protein, but also the estimation of CSF neurone-specific enolase
to be of diagnostic value.196,197 The latter marker is known to be elevated in a
variety of neurodegenerative processes affecting the central nervous system. As
in the case of minor elevations in CSF protein (37% of cases had a CSF protein
of greater than 0.4 grammes per litre in the current study), it may simply reflect
neuronal cell death and therefore lack specificity.
The interest in MR abnormalities in this condition has been mentioned. In
addition to the symmetrical pattern of high T2 signal arising from the basal
ganglia, a recent paper has described a single case with an asymmmetrical
pattern,198 This case, interestingly, manifested corresponding (asymmetrical)
abnormalities on electroencephalography and single photon emission
computerised tomography. In the present study, even in those cases where MR
examinations were performed, the finding was not universal. A symmetrical
abnormality was noted in three sporadic cases, but no consistent features in
their clinical characteristics were identified. Subsequent work from the unit has
established the poor sensitivity of this imaging modality in making a diagnosis of
CJD.199
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The study confirmed Met homozygosity at codon 129 as a "risk factor" for the
development of sporadic CJD (Figure 13), in keeping with Palmer et ats original
observation" and subsequent large series.101,102,200 When Met homozygosity at
this site is considered as a diagnostic test of sporadic CJD, and compared with
the genotype at codon 129 of non-CJD cases, the sensitivity is 0.8382 and the
specificity is 0.5000. To these apparently impressive figures must be added the
cases of familial CJD that would be diagnosed by a comprehensive genotypic
evaluation of the PRNP ORF. However, the positive predictive value of Met
homozygosity at codon 129 in the diagnosis of sporadic CJD in the community is
likely to be very low, given the rarity of this condition.
Finally, reference has been made in the introduction to a promising technique in
which biopsy of tonsil tissue (at autopsy) showed positive anti-PrP staining and
Western blot of tissue homogenate revealed protease-resistant PrP with
physiochemical characteristics similar to protease-resistant PrP from previously
diagnosed vCJD cases.166 Not only does this require replication ante mortem in
future vCJD cases, but it will be important to establish how often protease-
resistant PrP is identified in the tonsils of cases of sporadic, familial, and
iatrogenic CJD with central and peripheral routes of inoculation.
6.1.3 Ethical considerations
One other concern regarding the systematic surveillance of PRNP genotype in
suspected cases of CJD pertains to the ethical dilemmas posed, particularly by
the inadvertent discovery of a familial case. As noted, although these cases may
present at a younger age and have a longer duration of disease, their clinical
features are not different to sporadic cases. Furthermore, although a family
history is present in a large proportion, it is rarely identified as CJD or accepted
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as an autosomal dominantly inherited condition in which half of all offspring are
likely to develop disease. PRNP genome analysis has already been undertaken
in the screening of undiagnosed familial ataxic/dementing cases,201 and for pre-
symptomatic prediction in members of pedigrees with known inherited CJD.202 A
single case of pre-natal exclusion of GSS has also been reported.203 In the
current study, the acceptance rate for PRNP genome analysis was surprisingly
high at 73%. Counselling was carried out by the author, usually after relatives
had been informed about the progressive and incurable nature of the disease. At
the interview, an information sheet summarising the main points covered was
issued (Appendix 6), and the relative's signed consent was obtained. Relatives
were firstly requested to give their permission for genome testing, and if this was
given (as in all the cases) they were asked to indicate whether the result should
be disclosed to them or not (Appendix 7). As noted, the decision to know the
result of genome analysis was uninfluenced by the presence of a family history
of neurodegeneration, the direct implications for the respondent or the family's
level of education. In most cases, it was felt that the decision to know the result
of genome studies was taken with the belief that the test would show no risk to
remaining relatives.
7.1 Clinico-pathological correlation
The comparison of clinical features with the distribution of sponge in the
appropriate brain regions in cases showed little correlation (Table 23). The
methodological deficiencies inherent in this analysis which may have contributed
to this observation have already been mentioned. If valid, however, the
comparison raises several interesting issues. The distribution of sponge may not
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reflect neuronal loss, which may be a more important determiner of cerebral
dysfunction. The extent of involvement of the basal ganglia (93% of cases
examined revealed spongiform change in this region) is notable. Although extra¬
pyramidal features do occur in sporadic CJD, they are not common:
Parkinsonism, for example, was identified in only around a third of cases in this
series (Table 6). This lack of correlation between pathology on the one hand and
clinical disease on the other is matched by the lack of correlation between basal
ganglia high T2 signal on MR imaging and clinical features in CJD cases. Of the
three cases with this abnormality that were identified in the current study, one
patient did not manifest any features of extra-pyramidal dysfunction. It is
tempting to suggest even on the present limited data, that the abnormalities
noted on MR are a non-specific reflection of spongiosis.
At a more basic level, the lack of correlation may be attributable to our
incomplete understanding of function localisation within the cortex. Also, the
degree of neuronal plasticity (which may vary for different cell populations) could
have made the simplistic assignment of functions to brain regions meaningless.
In view of all these reservations, the apparent correlation between frontal lobe
dysfunction and sponge distribution (and a similar correlation in the cerebellum
which approaches statistical significance) could have arisen by chance. Whether
the association between neurone loss and sponge is different in these particular
regions is unknown. There may also be fundamental differences between the
behaviour of neurone populations in these regions (and their capacity to
withstand disease processes), and the behaviour of neurone populations in
regions of the brain where no correlation was found. The lack of correlation in
the occipital cortex is particularly interesting, given the relative confidence with
which blindness can be diagnosed and the early observations on Heidenhain's
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syndrome (the tendency for there to be prominent vacuolation affecting the
occipital cortex in these cases).21,5
7.1.1 Cases with anti-PrP positive plaques
In the cases studied, around 15% of sporadic CJD brains were found to exhibit
amyloid plaques, staining positively with anti-PrP. The systematic examination of
all cases in Edinburgh with immunocytochemistry is likely to make this
observation accurate. Analysis of the clinical characteristics of these cases
revealed that 55% presented with pure cerebellar dysfunction (an observation
that failed to reach statistical significance when compared with the presenting
features of the rest of the sporadic group). Typical EEG findings were recorded
in only 2/10 cases, but again this observation was not statistically significant in
comparison with the rest of the sporadic group.
There did appear to be an association between the presence of alleles encoding
Val at position 129 and the presence of anti-PrP positive amyloid plaques
(Figure15). Independent analysis of the clinical features in these cases revealed
that they were more likely to present with pure cerebellar dysfunction (Table 27
and Figure 14) and that typical EEGs were less likely to be recorded (Table 27).
The ages of onset and disease durations in these patients were no different from
patients who were Met homozygous (Table 26).
This apparently distinct clinical and neuropathological phenotype of sporadic
CJD raises an important issue. Does the phenotype result from the
"susceptibility" of individuals carrying the triplet encoding Val at codon 129 of the
PRNP ORF to develop CJD following contact with an (exogenous?) agent which
has a tendency to produce amyloid aggregates? Alternatively (and in the present
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author's view more plausibly), does it represent a marker of the disease process
in individuals with this genotype? If the latter interpretation is correct, further
study of these cases may reveal differences (from Met homozygous patients) in
their handling of the disease agent, or in the response of their neuronal
cytoarchitecture to the pathological process. It is of note that the rare Japanese
cases with this genotype show similar unicentric anti-PrP positive aggregates,
and that their cases are described as having "GSS" with progressive ataxia and
atypical EEGs.112
Since the completion of this study, Parchi and colleagues have published a
paper on sporadic CJD in which phenotypic variability was analysed according
to the Met/Val polymorphism at codon 129 of the PRNP ORF, and the
characteristics of PrP according to Western blotting and
immunohistochemistry.204The total number of patients studied was only 19. They
define four phenotypes on the basis of Met homozygosity, heterozygosity and
Val homozygosity, and two isoforms of protease-resistant PrP. Interestingly, they
too found that that the presence of codon 129 Val alleles was associated with
ataxic presentations, that only 1/6 patients with this genotype had typical EEG
appearances, and that all cases had "plaquelike and punctate" patterns of anti-
PrP immunostaining. The authors conclude that their data argues in favour of
distinct prion variants (probably defined by the two isoforms of protease-resistant
PrP) affecting humans, although the rest of the phenotypic variability is
(presumably) determined by the host genotype. In favour of these authors'
hypothesis was the observation that the two types of protease-resistant PrP in
Met homozygous patients produced two distinct phenotypes, with the "type 2"
being associated with a longer duration of disease. However, this observation
was based only on two cases.
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8.1 Whither the prion theory?
It would be inappropriate to argue for or against the prion hypothesis purely on
the basis of an observational study of the clinical characteristics of CJD. As it
stands, however, the theory has some difficulties in accounting for some of the
observations that have been made in this study, and elsewhere.
1. If younger sporadic cases are likely to have a more efficient
polymerisation process involving homologous PrP molecules to account for their
younger age of onset, why is the disease duration in these cases also not
shorter? In fact these cases are noted to have a longer disease duration.
Presumably, other factors such as the well being of organ systems, more
efficient metabolism and better immune function all contribute to the enhanced
survival, but it is notable that the neurodegenerative process (particularly if
determined by PrP interactions) does not appear to have the dominant role.
2. If sporadic disease occurs purely as a result of the spontaneous
conversion of PrPc to PrPSc, why is there no progressive increase in age-
specific incidence with increasing age? (The opportunity for this kind of
transformation would increase with increasing age.) It has been argued that case
ascertainment in the elderly is imprecise, and that cases are systematically
missed even with intensive surveillance. An increase in elderly cases has been
recorded during the period of the current UK surveillance study,161,205 but the fall-
off in age-specific incidence with increasing age continues to be noted. The
latter observation has been confirmed in a recent study from Austria in which the
latest available incidence value (for 1995) for necropsy-confirmed CJD was
1.25/million, implying near complete case ascertainment.190 Over the whole
period of study (from 1969 to 1995), the number of cases fell progressively from
19 in the group aged 60 to 64 years, to 2 in the group aged 80 to 84 years.
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Furthermore, as already explained, in unselected post-mortem studies of the
very old, the diagnosis of (unsuspected) CJD is rare.188 It is likely therefore that
the reduction in age-specific CJD incidence with increasing age is a real
observation, needing modification of the prion protein theory to account for it
satisfactorily.
3. If the homology of PrP molecules is so critically influenced by the amino
acids encoded by codon 129 of the PRNP ORF,95 why is there no observed
tendency for sporadic CJD cases which are heterozygous at this site to have
older ages of onset and/or longer disease durations (Table 26)? A similar lack of
effect of this site of common polymorphism on age of onset and disease duration
was observed in the pooled familial data. Once again, there may be other factors
governing PrP interactions that have a more fundamental influence on age of
presentation and disease duration, than the poymorphic status at codon 129.
4. If homologous PrP interactions are so crucial, would the population
incidence of sporadic CJD not be determined by the prevalence of Met-encoding
alleles (at codon 129)? In populations where Met homozygosity is virtually
universal (such as the Japanese) the incidence of CJD is no different.35
5. Attention has been drawn to the difficulties experienced in attributing
phenotypic variability in familial CJD cases to sites of genetic influence purely
within the PRNP ORF.107'194 If there are other sites of importance within the
human genome that are implicated in familial CJD, PrP interactions may emerge
as less critical in the susceptibility to the development and propagation of CJD in
general.
These criticisms can be countered by the wealth of observational and
experimental data which is in favour of the prion hypothesis. The recent
modification of the theory in which another protein (protein X), which functions
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as a species-specific molecular chaperone in the formation of PrPSc, is evoked
may account for some of the discrepancies.97 Could, for example, the putative
protein X be encoded by a gene outwith PRNP in humans?
9.1 Can the BSE risk to humans be assessed clinically?
Following the period of study in this thesis, an apparently novel form of
Creutzfeldt-Jakob disease has been identified. Fourteen cases of this vCJD
have been confirmed to-date in the UK,206 and a further case has been reported
from France. As discussed in the introduction (page 32), vCJD appears to be
characterised by unique neuropathological features and unusual clinical
characteristics. In contrast with the data presented here on patients with CJD
identified between 1990 and 1994, vCJD patients do appear to be quite different.
However, it would be unwise to associate this phenotype as being aetiologically
related to BSE purely on this evidence. (It is not: compelling laboratory data has
emerged within the past year to support an association. Transmission of BSE by
intracerebral inoculation into macaques produced strikingly similar pathological
appearances,207 and experimental studies on disease-related PrP isoforms from
patients with vCJD appear to show physiochemical similarities between
protease-resistant PrP derived from these patients and protease-resistant PrP
from BSE tissue.165,208) It is likely that our appreciation of the spectrum of
disorders associated with spongiform encephalopathy and their clinical
presentations is incomplete. Alpers' disease is a case in point. This rare
childhood progressive encephalopathy is associated with cerebral spongiform
change,209 and in certain hands has been successfully transmitted to laboratory
animals.210 Nevertheless, it is still not established whether this disease should be
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considered as a human spongiform encephalopathy. Consequently, it is
conceivable that vCJD is not a new phenomenon, and that these cases were not
considered as a spongiform encephalopathy on account of their atypical
presentations. Their identification at this point in time could have been
secondary to the intensity of the surveillance effort in the UK. This seems an
unlikely explanation, however, and intensive retrospective studies on post
mortem tissue and on-going surveillance efforts in Europe and the US have not
identified any other cases of vCJD (up to now). The geographical isolation of
vCJD to the UK (mostly) need not imply an association with BSE either.
Panencepahlopathic CJD as has been noted appears to be found in Japan only.
Whether or not vCJD proves to be associated with BSE, if successfully
transmitted, it will extend the spectrum of human spongiform encephalopathy as
currently understood.
One key observation with respect to vCJD is the currently identified (young) age
of onset. It is not readily apparent why BSE (if the aetiological factor) should be
a particular risk to young humans. One concern is that these cases have come
to the attention of clinicians simply because of their unusual age, and that cases
presenting at older ages will be "diluted" by classical CJD cases. Formal
descriptions of the clinical characteristics of vCJD are in preparation (M. Zeidler,
personal communication), but presentations of CJD cases with pure psychiatric
features or sensory symptoms should alert clinicians to the possibility of vCJD.
In response to the question posed at the start of this section, clinical surveillance
may not constitute the entirety or even the mainstay of the scientific effort for
answering this important question. However, without continued clinical vigilance
(backed up by the systematic neuropathological examination of central nervous
system tissue) it is unlikely to succeed.
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Legend for Table 1: The transmissible spongiform encephalopathies
'Includes Gerstmann-StrMussler syndrome and Fatal
Familial Insomnia
These disorders are suspected or proven to be related to
Bovine Songiform Encephalopathy

























Table 2: Cases described by A. Jakob14
Patient Age Duration of illness Clinical course "Differential"*






2 34 years 1.5 months'* Psychomotor disturbance
Incontinence
Broad-based + spastic gait
Limb rigidity
Mask-like facies, slow + monotonous
speech
Epilepsy
3 42 years 9 months Disturbed ocular movements
Disturbed speech + writing









Differential diagnoses suggested by W.R. Kirschbaum.17
Kirschbaum estimates the duration of disease in this patient to be 6 months.17 Jakob's original case description states that the patient died 6 weeks after the onset of symptoms.1*
?Malnutrition
(NB ex-alcohol abuse)
Legend for Table 3: Comparison of clinical features at the onset and during the
course of illness in three series
Table 3: Comparison of clinical features
Clinical feature Will and Matthews, 198442 Brown etal, 198640 Brown etal, 199441
Onset Course Onset Course Onset Course
Cognitive impairment 21% 100% 64% 100% 69% 100%
Cerebellar dysfunction 19% 42% 34% 61% 33% 71%
Visual failure 9% 13% 17% 42% 19% 42%
Pyramidal disease 79%a 2% 43% 2% 62%
Extra-pyramidal disease 3%a 2% 67% 0.5% 56%
Lower motor neurone signs - 3% 0.4% 11% 0.5% 12%
Seizures ?r/ob 9% 0.4% 8% 0% 19%
Myoclonus ?5%c 82% 0% 88% 1% 78%
aPresence of rigidity alone was classified as "pyramidal"
b"Blackout attacks"
c"lnvoluntary movements"




























































































NFTs = Neurofibrillary tangles **ATD = Alzheimer's disease
Legend for Table 5: Comparison of the ages of onset and disease durations of
sporadic, familial and iatrogenic CJD cases studied here
Familial cases presented a decade earlier (comparison a),
and had disease durations that were twice as long
(comparison b).
The disease duration of iatrogenic cases was no different
from sporadic ones (comparison d).





(b) z - 2.2424
(°) z - 5.6985
(d) z- 1.7985
Age of onset (years) Disease duration (months)






















p < 0.0001 Corrected for ties
p = 0.0249 - do -
p < 0.0001 - do -
p = 0.0721 - do -
Table 6: Frequency of clinical signs at different stages of sporadic CJD
Clinical feature At presentation Early course During illness
Cognitive - Personality 14% (20) 51% ( 73) 53% ( 76)
Behaviour 15% (22) 52% ( 74) 62% ( 89)
Memory 19% (27) 57% ( 81) 64% ( 91)
Disorientation 15% (21) 62% ( 88) 78% (112)
Dysphasia - Expressive 4% ( 6) 27% ( 39) 38% ( 55)
Receptive 0% ( 0) 5% ( 7) 20% ( 28)
Dyspraxia 3% ( 5) 44% ( 63) 55% ( 79)
Pyramidal dysfunction 3% ( 4) 20% ( 28) 62% ( 88)
Extra-pyramidal - Parkinsonism 1% ( 1) 13% ( 18) 34% ( 48)
Chorea 1% ( 1) 4% ( 6) 13% ( 18)
Dystonia 0% ( 0) 6% ( 8) 16% ( 23)
Myoclonus 1% ( 1) 35% ( 50) 85% (122)
Epilepsia partialis continua 0% ( 0) 2% ( 3) 4% ( 6)
Visual - blindness 9% (13) 35% ( 50) 52% ( 75)
hallucinations 1% ( 2) 21% ( 30) 32% ( 46)
Cerebellar- incoordination 39% (56) 76% (109) 85% (122)
nystagmus 0% ( 0) 10% ( 15) 20% ( 29)
Oculomotor disturbance 1% ( 1) 14% ( 20) 27% ( 38)
Bulbar dysfunction - 2% ( 3) 8% ( 12)
Muscle wasting - 1% ( 2) 17% ( 24)
Incontinence - 16% ( 23) 39% ( 56)
Primitive reflexes - - 58% ( 83)
Facial weakness - - 16% ( 23)
Paratonic rigidity - - 38% ( 55)
Seizures - - 13% ( 19)
Akinetic mutism - - 75% (107)
Respiratory depression - - 15% ( 22)
Legend for Table 7: The frequency of key clinical features in definite (n = 120)
and probable (n = 23) sporadic CJD cases
Myoclonus, akinetic mutism and especially cortical














Pyr, Par or C
Definite 84% (101) 49% (59) 72% (87) 62% (74) 50% (60) 87% (104) 98% (117)
Probable 91% (21) 70% (16) 87% (20) 61% (14) 6iy0 (14) 78% (18) 96% (22)
N.B. Data available in 120 definite and 23 probable cases.
Table 8: CJD of long duration
Reference Age Sex Duration* Clinical" EEG PRNP Pathology
003 60 F 17 COB first Non- N/A N/A
(Heidenhain's) diag.
067 75 M 14 COG first Diag. N/A Diffuse spongiosis
"Classical"
105 65 F 13 CER first Non- 129 Diffuse spongiosis
Cerebellar syn. diag. MV Plaques
109 77 F 14 CER first Diag. N/A Diffuse spongiosis
"Classical"
113 60 M 15 COG + CER Diag. 129 Diffuse spongiosis
"Classical" MM
148 60 M 14 CER first Non- 129 Diffuse spongiosis
"Classical" diag. MM
161 56 M 17 OTH first Diag. N/A Diffuse spongiosis
Parkinsonian
194 60 M 15 COG + CER Non- N/A Diffuse spongiosis
"Classical" diag.
201 53 F 17 CER first Diag. 129 N/A
"Classical" MM
207 66 M 15 COG first Non- N/A Diffuse spongiosis
"Classical" diag.
221 63 F 12 CER first Non- N/A N/A
"Classical" diag.
225 71 M 22 OTH first Non- 129 N/A
"Classical" diag. MM
316 57 M 13 COG first Non- N/A N/A
"Classical" diag.
339 65 M 12 CER first Non- N/A N/A
"Classical" diag.
251 51 M 62 COG first Non- N/A Diffuse spongiosis
"Classical" diag.
135 44 F 62 COG first Non- N/A Diffuse spongiosis
"Classical" diag. Plaques
237 72 F 28 COG first N/A N/A N/A
"Classical"
152 46 F 45 COG first N/A N/A N/A
"Classical"
159 74 M 30 OTH first Diag. 129 N/A
"Classical" MM
282 59 F 26 COG first Non- N/A N/A
"Classical" diag.
N.B. "Duration of disease in months
**COG = cognitive dysfunction / CER = cerebellar incoordination / COB = cortical blindness / OTH = an
alternative first clinical sign
N/A = information not available
Some of the cases have been pathologically confirmed as CJD in other centres
Table 9: Results of investigations in sporadic CJD cases
Investigation Postive/abnormal Negative/normal No data Percentage
Positive Negative
EEG 61 72 11 46% 54%
Liver enzymes 58 64 22 48% 52%
CSF 32 54 58 37% 63%
CT/MRI 80 56 8 59% 41%











Table 11: Cases of familial CJD














046 178 MM F 61 14 ?CJD Yes Non-diag. FFI
050 200 MM F 67 1 CJD Yes* Diag. CJD
056 +96 bpi** MM M 56 3 CJD N/A Diag. CJD
122 200 MM M 56 4 CJD Yes Diag. CJD
145 102 MV F 56 8 ?CJD Yes Non-diag. ?GSS
165 N/A N/A M 66 20 CJD Yes N/A N/A
172 200 MM F 43 7 CJD No Diag. CJD
173 + 144 bpi** MV M 46 3 CJD Yes Diag. CJD
210 102 MV F 54 40 ?CJD Yes Non-diag. N/A
234 102 N/A F 43 Alive ?ATD*** Yes Non-diag. -
219 178 MM F 39 10 ?CJD No Non-diag. FFI
291 102 N/A M 57 8 ?ATD/?GSS Yes Non-diag. GSS
301 +144 bpi** N/A M 35 112 ?ATD Yes N/A
"Atypical priondementia'"127J 28
309 117 N/A F 43 Alive GSS Yes Non-diag. -
N.B. * Of Libyan Jewish extraction
** Extra base-pair insertions in the octapeptide repeat region
***
Alzheimer-type dementia
Table 12: Clinical characteristics of familial CJD (n = 14)
Clinical feature At presentation Early course During illness
Cognitive - Personality 21% (3) 36% ( 5) 43% ( 6)
Behaviour 21% (3) 50% ( 7) 64% ( 9)
Memory 14% (2) 43% ( 6) 64% ( 9)
Disorientation 14% (2) 79% (11) 86% (12)
Dysphasia - Expressive 7% (1) 43% ( 6) 64% ( 9)
Receptive 0% (0) 7% ( 1) 36% ( 5)
Dyspraxia 0% (0) 36% ( 5) 71% (10)
Pyramidal dysfunction 0% (0) 7% ( 1) 36% ( 5)
Extra-pyramidal - Parkinsonism 0% (0) 21% ( 3) 29% ( 4)
Chorea 0% (0) 0% ( 0) 14% ( 2)
Dystonia 0% (0) 0% ( 0) 14% ( 2)
Myoclonus 0% (0) 50% ( 7) 86% (12)
Epilepsia partialis continua 0% (0) 0% ( 0) 0% ( 0)
Visual - blindness 7% (1) 21% ( 3) 36% ( 5)
hallucinations 0% (0) 29% ( 4) 29% ( 4)
Cerebellar- incoordination 21% (3) 71% (10) 86% (12)
nystagmus 0% (0) 0% ( 0) 14% ( 2)
Oculomotor disturbance 0% (0) 21% ( 3) 36% ( 5)
Bulbar dysfunction - 7% ( 1) 14% ( 2)
Muscle wasting - 0% ( 0) 14% ( 2)
Incontinence - 29% ( 4) 43% ( 6)
Primitive reflexes - - 71% (10)
Facial weakness - - 7% ( 1)
Paratonic rigidity - - 50% ( 7)
Seizures - - 14% ( 2)
Akinetic mutism - - 50% ( 7)
Respiratory depression - - 0% ( 0)
Legend for Table 13: Analysis by Spearman rank correlation of the clinical
features of sporadic and familial CJD, at different
stages of illness (see also Appendix 4)
At each of these points, the two groups show
no differences.
Table 13: Rank correlation of clinical features, between sporadic and familial cases of CJD
Stage Rs t df P
At presentation 0.8695 7.042 16 <0.0001
Early 0.9032 9.172 19 <0.0001
During course 0.9043 10.592 25 <0.0001
N.B. All calculations corrected for ties
Table 14: Clinical characteristics of iatrogenic CJD with "peripheral" route of inoculation (n = 9)
Clinical feature At presentation Early course During illness
Cognitive - Personality 0% (0) 22% (2) 33% (3)
Behaviour 0% (0) 0% (0) 11% (1)
Memory 11% (1) 11% (1) 56% (5)
Disorientation 0% (0) 0% (0) 22% (2)
Dysphasia - Expressive 0% (0) 0% (0) 0% (0)
Receptive 0% (0) 0% (0) 0% (0)
Dyspraxia 0% (0) 11% (1) 33% (3)
Pyramidal dysfunction 0% (0) 0% (0) 22% (2)
Extra-pyramidal - Parkinsonism 0% (0) 0% (0) 11% (1)
Chorea 0% (0) 11% (1) 11% (1)
Dystonia 0% (0) 0% (0) 0% (0)
Myoclonus 0% (0) 44% (4) 78% (7)
Epilepsia partialis continua 0% (0) 0% (0) 0% (0)
Visual - blindness 0% (0) 0% (0) 0% (0)
hallucinations 0% (0) 0% (0) 0% (0)
Cerebellar- incoordination 89% (8) 100% (9) 100% (9)
nystagmus 0% (0) 33% (3) 56% (5)
Oculomotor disturbance 0% (0) 22% (2) 56% (5)
Bulbar dysfunction - 0% (0) 11% (1)
Muscle wasting - 11% (1) 11% (1)
Incontinence - 22% (2) 44% (4)
Primitive reflexes - - 33% (3)
Facial weakness - - 11% (1)
Paratonic rigidity - - 0% (0)
Seizures - - 0% (0)
Akinetic mutism - - 44% (4)
Respiratory depression - - 0% (0)
Legend for Table 15: Analysis by Spearman rank correlation of the clinical
features of sporadic and iatrogenic CJD via
"peripheral" routes of inoculation, at different stages
of illness (see also Appendix 4)
There is a significant difference in phenotype during
early disease.
Table 15: Rank correlation of clinical features, between sporadic and iatrogenic cases of CJD with "peripheral" routes of
inoculation
Stage Rs t df P
At presentation 0.5554 2.671 16 0.0167
Early 0.2117 0.944 19 0.3570
During course 0.6054 3.803 25 0.0008
* *
N.B. All calculations corrected for ties
:
Table 16: Cases with (pathologically confirmed) non-CJD
Diagnosis Frequency
Alzheimer-type dementia (ATD) 17
ATD + Multi-infarct disease (MID) 5
MID 3
Diffuse Lewy body disease (DLBD) 1
ATD + DLBD 1













Table 17: Comparison of clinical features at presentation, between CJD and non-CJD cases
Clinical feature CJD Non-CJD Sensitivity Specificity +ve PV -ve PV
Cognitive - Personality 23 4 0.1465 0.8889 0.8519 0.1928
Behaviour 25 1 0.1592 0.9722 0.9615 0.2096
Memory 29 9 0.1847 0.7500 0.7632 0.1742
Disorientation 23 11 0.1465 0.6944 0.6765 0.1572
Dysphasia - Expressive 7 2 0.0446 0.9444 0.7778 0.1848
Receptive 0 0 0.0000 1.0000 - 0.1865
Dyspraxia 5 1 0.0318 0.9722 0.8333 0.1872
Pyramidal dysfunction 4 1 0.0255 0.9722 0.8000 0.1862
Extra-pyramida Parkinsonism 1 1 0.0064 0.9722 0.5000 0.1832
Chorea 1 0 0.0064 1.0000 1.0000 0.1875
Dystonia 0 0 0.0000 1.0000 - 0.1865
Myoclonus 1 0 0.0064 1.0000 1.0000 0.1875
Epilepsia partialis continua 0 0 0.00Q0 1.0000 - 0.1865
Visual - blindness 14 1 0.0892 0.9722 0.9333 0.1966
hallucinations 2 1 0.0127 0.9722 0.6667 0.1842
Cerebellar - incoordination 59 2 0.3758 0.9444 0.9672 0.2576
nystagmus 0 0 0.0000 1.0000 . 0.1865
Oculomotor disturbance 1 1 0.0064 0.9722 0.5000 0.1832
Table 18: Comparison of clinical features during the early phase of illness, between CJD and non-CJD cases
. Clinical feature CJD Non-CJD Sensitivity Specificity +ve PV -ve PV
Cognitive - Personality 78 11 0.4968 0.6944 0.8764 0.2404
Behaviour 81 13 0.5159 0.6389 0.8617 0.2323
Memory 87 20 0.5541 0.4444 0.8131 0.1860
Disorientation 99 23 0.6306 0.3611 0.8115 0.1831
Dysphasia - Expressive 45 4 0.2866 0.8889 0.9184 0.2222
Receptive 8 2 0.0510 0.9444 0.8000 0.1858
Dyspraxia 68 19 0.4331 0.4722 0.7816 0.1604
Pyramidal dysfunction 29 8 0.1847 0.7778 0.7838 0.1795
Extra-pyramida Parkinsonism 21 7 0.1338 0.8056 0.7500 0.1758
Chorea 6 0 0.0382 1.0000 1.0000 0.1925
Dystonia 8 0 0.0510 1.0000 1.0000 0.1946
Myoclonus 57 10 0.3631 0.7222 0.8507 0.2063
Epilepsia partialis continua 3 0 0.0191 1.0000 1.0000 0.1895
Visual - blindness 53 5 0.3376 0.8611 0.9138 0.2296
hallucinations 34 6 0.2166 0.8333 0.8500 0.1961
Cerebellar - incoordination 119 8 0.7580 0.7778 0.9370 0.4242
nystagmus 15 1 0.0955 0.9722 0.9375 0.1977
Oculomotor disturbance 23 1 0.1465 0.9722 0.9583 0.2071
Bulbar dysfunction 4 1 0.0255 0.9722 0.8000 0.1862
Muscle wasting 2 2 0.0127 0.9444 0.5000 0.1799
Incontinence 27 11 0.1720 0.6944 0.7105 0.1613
Table 19: Comparison of clinical features during the course of illness, between CJD and non-CJD cases
Clinical feature CJD Non-CJD Sensitivity Specificity +ve PV -ve PV
Cognitive - Personality 82 13 0.5223 0.6389 0.8632 0.2347
Behaviour 98 18 0.6242 0.5000 0.8448 0.2338
Memory 100 21 0.6369 0.4117 0.8264 0.2083
Disorientation 124 27 0.7898 0.2500 0.8212 0.2143
Dysphasia - Expressive 64 12 0.4076 0.6667 0.8421 0.2051
Receptive 33 5 0.2102 0.8611 0.8684 0.2000
Dyspraxia 89 19 0.5669 0.4722 0.8241 0.2000
Pyramidal dysfunction 93 20 0.5924 0.4444 0.8230 0.2000
Extra-pyramidal - Parkinsonism 52 11 0.3312 0.6944 0.8254 0.1923
Chorea 20 2 0.1274 0.9444 0.9091 0.1988
Dystonia 25 1 0.1592 0.9722 0.9615 0.2096
Myoclonus 134 20 0.8535 0.4444 0.8701 0.4103
Epilepsia partialis continua 6 0 0.0382 1.0000 1.0000 0.1925
Visual - blindness 80 6 0.5096 0.8333 0.9302 0.2804
hallucinations 50 6 0.3185 0.8333 0.8929 0.2190
Cerebellar- incoordination 134 14 0.8535 0.6111 0.9054 0.4889
nystagmus 31 1 0.1975 0.9722 0.9688 0.2174
Oculomotor disturbance 43 4 0.2739 0.8889 0.9149 0.2192
Bulbar dysfunction 14 3 0.0892 0.9167 0.8235 0.1875
Muscle wasting 26 6 0.1656 0.8333 0.8125 0.1863
Incontinence 62 14 0.3949 0.6111 0.8158 0.1880
Primitive reflexes 93 16 0.5924 0.5556 0.8532 0.2381
Facial weakness 24 5 0.1529 0.8611 0.8276 0.1890
Paratonic rigidity 62 10 0.3949 0.7222 0.8611 0.2149
Seizures 21 6 0.1338 0.8333 0.7778 0.1807
Akinetic mutism 114 8 0.7261 0.7778 0.9344 0.3944
Respiratory depression 22 7 0.1401 0.8056 0.7586 0.1768
Table 20: Comparison of clinical features between pathologically confirmed (other) and pathologically unconfirmed
(other#) cases of non-'C'JD, at' presentation
Clinical feature Non-CJD (n = 36)
+ PM
Non-CJD (n = 30)
+ No PM
Cognitive - Personality 4 (11%) 7 (23%)
Behaviour 1 ( 3%) 2 ( 7%)
Memory 9 (25%) 15 (50%)
Disorientation 11 (31%) 10 (33%)
Dysphasia - Expressive 2 ( 6%) 2 ( 7%)
Receptive 0 ( 0%) 0 ( 0%)
Dyspraxia 1 ( 3%) 0 ( 0%)
Pyramidal dysfunction 1 ( 3%) 0 ( 0%)
Extra-pyramidal - Parkinsonism 1 ( 3%) 2 ( 7%)
Chorea 0 ( 0%) 1 ( 3%)
Dystonia 0 ( 0%) 0 ( 0%)
Myoclonus 0 ( 0%)'- 0 ( 0%)
Epilepsia partialis continua 0 ( 0%) 0 ( 0%)
Visual - blindness 1 ( 3%) 0 ( 0%)
hallucinations 1 ( 3%) 2 ( 7%)
Cerebellar- incoordination 2 ( 6%) 7 (23%)
nystagmus 0 ( 0%) 0 ( 0%)
Oculomotor disturbance 1 ( 3%) 0 ( 0%)
Table 21: Comparison of clinical features between pathologically confirmed (other) and pathologically unconfirmed
(other#) cases of non-CJD, early in the course
Clinical feature Non-CJD
+ PM
(n = 36) Non-CJD
+ no PM
(n = 30)
Cognitive - Personality 11 (31%) 9 (30%)
Behaviour 13 (36%) 8 (27%)
Memory 20 (56%) 19 (63%)
Disorientation 23 (64%) 16 (53%)
Dysphasia - Expressive 4 (11%) 5 (17%)
Receptive 2 ( 6%) 1 ( 3%)
Dyspraxia 19 (53%) 9 (30%)
Pyramidal dysfunction* 8 (22%) 2 ( 7%)
Extra-pyramidal - Parkinsonism 7 (19%) 2 ( 7%)
Chorea 0 ( 0%) 3 (10%)
Dystonia 0 ( 0%) 0 ( 0%)
Myoclonus 10 (28%) 15 (50%)
Epilepsia partialis continua 0 ( 0%) 0 ( 0%)
Visual - blindness** 5 (14%K 0 ( 0%)
hallucinations 6 (17%) 6 (20%)
Cerebellar- incoordination 8 (22%) 10 (33%)
nystagmus 1 ( 3%) 1 ( 3%)
Oculomotor disturbance 1 ( 3%) 0 ( 0%)
Bulbar dysfunction 1 ( 3%) 0 ( 0%)
Muscle wasting 2 ( 6%) 0 ( 0%)
Incontinence*** 11 (31%) 0 ( 0%)
RR = 1.60, 95% CIS = 1.07-2.40
RR = 1.97, 95% CIs = 1.54 - 2.52
RR = 2.20, 95% CIS = 1.65 - 2.94
Table 22: Comparison of clinical features between pathologically confirmed (other) and pathologically unconfirmed (other#)
cases of non-CJD, during illness
Clinical feature Non-CJD
+ PM
(n = 36) Non-CJD
+ no PM
(n = 30)
Cognitive- Personality 13 (36%) 10 (33%)
Behaviour 18 (50%) 13 (43%)
Memory 21 (58%) 22 (73%)
Disorientation 27 (75%) 19 (63%)
Dysphasia - Expressive 12 (33%) 10 (33%)
Receptive 5 (14%) 5 (17%)
Dyspraxia 19 (53%) 14 (47%)
Pyramidal dysfunction 20 (56%) 13 (43%)
Extra-pyramidal - Parkinsonism 11 (31%) 5 (17%)
Chorea 2 ( 6%) 6 (20%)
Dystonia 1 ( 3%) 0 ( 0%)
Myoclonus 20 (56%) 20 (67%)
Epilepsia partialis continua 0 ( 0%) 0 ( 0%)
Visual - blindness 6 (17%) 2 ( 7%)
hallucinations 6 (17%) 7 (23%)
Cerebellar- incoordination 14 (39%) 13 (43%)
nystagmus 1 ( 3%k 1 ( 3%)
Oculomotor disturbance 4 (11%) 0 ( 0%)
Bulbar dysfunction 3 ( 8%) 0 ( 0%)
Muscle wasting 6 (17%) 3 ( 1%)
Incontinence 14 (39%) 6 ( 2%)
Primitive reflexes 16 (44%) 10 (33%)
Facial weakness* 5 (14%) 1 ( 3%)
Paratonic rigidity 10 (28%) 7 (23%)
Seizures 6 (17%) 6 (20%)
Akinetic mutism** 8 (22%) 1 ( 3%)
Respiratory depression*** 7 (19%) 0 ( 0%)
*RR = 1.61, 95% CIs = 1.05 - 2.49 **RR = 1.81, 95% CIs = 1.27 - 2.57 . ***RR = 2.03, 95% CIs = 1.57 - 2.64
Table 23: Comparison of clinical and pathological features in different
areas of CJD brain
Area Clinical Pathology Chi square Significance*
Sponge + Sponge -
Frontal Signs + 43 15 7.09 0.0077
Signs - 5 10
Temporal Signs + 43 8 0.15 0.7031
Signs - 20 2
Parietal Signs + 32 16 ' 0.00 0.9744
Signs - 16 9
Basal ganglia Signs + 30 4 1.18 0.2766
Signs - 38 1
Occipital Signs + 31 8 0.00 0.9902
Signs - 28 6
Cerebellar Signs + 58 3 3.03 0.0818
Signs - 9 3
>
Brainstem Signs + 1 7 0.31 0.5794
Signs - 8 57
All calculations with df = 1 and Yates' correction
Table 24: Sporadic CJD cases with anti-PrP positive amyloid plaques
Case • Age Sex Duration Clinical* EEG** Sponge*** Codon 129
genotype**










229 61 F 7 COG presentation; classical Non-diag. Parieta l/BG/Occi pita 1/
Cerebellar
N/A
227 60 M 4 CER presentation; classical Non-diag. Frontal/Temporal/Parietal/
BG/Occipital/Cerebellar
W
244 63 F 9 CER presentation; classical Non-diag. Frontal/Temporal/Parietal/
BG/Occipital/Cerebellar
MV
265 75 M 3 CER presentation; classical N/A Temporal/BG/Occipital/
Cerebellar/Brainstem
N/A
257 56 F 3 COG presentation; classical Diagnostic Frontal/Temporal/Parietal/
Occipital/Brainstem
MM
304 76 F 5 COG presentation; classical Diagnostic Frontal/Temporal/Parietal/
Occipital/Cerebellar
N/A
283 78 F 4 COG presentation; classical Non-diag. Frontal/Temporal/BG/
Occipital/Cerebellar
N/A
147 65 M 2 CER presentation; classical Non-diag. Frontal/Temporal/Parietal/
BG/Occipital/Cerebellar
N/A
305 75 F 4 CER presentation; classical Non-diag. Frontal/Temporal/Parietal/
BG/Cerebellar
N/A
N.B. *CER = cerebellar / COG = cognitive dysfunction
**N/A = data not available
***BG = basal ganglia
Table 25: Comparisons of the age§,of on$et and disease durations between familial CJD cases, homozygous and
heterozygous with respect to the common polymorphism at codon 129
Codon 129 genotype No. Age at onset (yrs) Disease duration (mnths)
Mean Range Median Mean Range Median
MM 6 54* 39-67 56 -Jkk 1 -14 6
MV 3 52* 46-56 54 17** 3-40 8
W 0 - - - _ _
•k
kk
Mann Whitney U = 7.0; not significant
Mann Whitney U = 6.5; not significant
Table 26: Comparison of ages of onset and disease durations between sporadic CJD cases with different codon 129
genotypes
Genotype Age (years) Duration (months)
No. Mean Range Median No. Mean Range Median
MM 57 66 49-86 66 55 5 1 -30 3
MV 6 67 61 -79 65 6 6 2 -13 4
W 5 58 48-63 59 5 ^ 5 1 -10 4
Table 27: Clinical and pathological features of sporadic CJD cases




Clinical features* EEG Pathology**
57 MV CER first; then classical Non-diag. Temporal, parietal and cerebellar
sponge
105 MV
CER first; progressive cerebellar
syndrome
Non-diag.
Frontal, temporal, basal ganglia,
occipital and cerebellar sponge.
Anti-PrP positive plaques




Frontal, temporal, parietal, basal
ganglia, occipital, cerebellar and
brainstem sponge
162 MV CER first; then classical Diagnostic N/A
244 MV CER first; then classical Non-diag.
Frontal, temporal, parietal, basal
ganglia, occipital and cerebellar
sponge. Anti-PrP positive plaques
250 MV
CER with cortical deafness at
start; then classical
Non-diag.
Frontal, temporal, basal ganglia,
occipital and cerebellar sponge
27 VV CER first; then classical Non-diag. N/A
97 VV
COG and CER dysfunction at
start; then classical
Non-diag. Temporal, basal ganglia, occipital
and cerebellar sponge
125 VV CER first; then classical Non-diag.
Frontal, temporal, parietal, basal




VV CER first; then classical Non-diag.
Frontal, temporal, parietal, basal
ganglia, occipital and cerebellar
sponge
227 VV CER first; then classical Non-diag.
Frontal, temporal, parietal, basal
ganglia, occipital and cerebellar
sponge. Anti-PrP positive plaques
NB *CER = cerebellar / COG = cognitive dysfunction as first features
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Figure 1: H.G. Creutzfeldt (b 1883)
Figure 2: A.Jakob (1884-1931)
Legend for Figure 3: Diagram illustrating the proposed interaction of
nascent, protease-sensitive prion protein (blue boxes,
PrPc) with infective, protease-resistant prion protein
(red balls, PrPSc). The theory holds that the process
is auto-catalytic, therefore converting more PrPc to
PrPSc.
Figure3:InteractionofPrP^withrP^c,anditsconversionPrP^c
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Figure 5: Correlation of disease duration with
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Figure 8. Two EEGs from (pathologically confirmed) case of CJD, performed
6 days apart
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Figure 12: Amyloid plaques in CJD. Immunocytochemistry for prion protein is
demonstrated (avidin-biotin reaction after hydrolytic autoclaving
and hematoxylin counterstain, originally x 240).
t,
a) In case 145, carrying Pro - Leu mutation at codon 102. Multicentric
plaques are present, but they are not large and confluent (as seen
in GSS).
b) In case of sporadic CJD. The plaques are unicentric.
LegendforFigure13:















Figure 13: Comparison of codon 129 genotype
Figure 14: Comparison of presenting clinical features
Legend for Figure 14: Comparison of the presenting clinical features
between cases that were Met homozygous at codon
129 (blue columns), and cases bearing Val alleles
(green columns) at this site
Cerebellar dysfunction as a presenting feature is
commoner in cases that are heterozygous or Val
homozygous.
Figure 15: Codon 129 genotype in PrP+ve and -ve cases
Legend for Figure 15: Polymorphic status at codon 129 in sporadic CJD
cases exhibiting (PrP +ve) and not exhibiting (PrP
-ve) unicentric plaques
Met homozygous cases are shown in blue;
heterozygous and Val homozygous cases are shown
in green.
Cases bearing Val alleles are more likely to manifest
plaques.
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(n = 84) /
MZ 205,251,299,316,339
(n = 5)
RDS All other cases
(n = 104)





Appendix 2: Data extracted from clinical record




















Oculomotor disturbance As * , plus
•- ' Bulbar dysfunction
Muscle wasting
l








Appendix 3: Patients whose molecular biological examinations were
performed at St. Mary's Hospital.
1, 2, 9,13, 20, 21, 27, 43, 45, 46, 47, 50, 56, 57, 68, 234, 291,
301, 309, 19, 34, 39, 53, 55, 33, 51
(n = 26)
i
Legend for Appendix 4 Frequency of clinical features in sporadic, familial
and iatrogenic (via "peripheral" inoculation) CJD, at
various stages of illness
Columns 1 - 3: at presentation
Columns 4-6: early in course
Columns 7 - 9: during illness
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Legend for Appendix 5: Comparison of the presence of spongiform change in
different areas of the brain with features of
neurological dysfunction attributable to that
region
A total of 73 cases have been studied: the case
reference numbers are given in the left-hand column.
The areas considered are frontal lobe, temporal lobe,
parietal lobe, basal ganglia, occipital lobe, cerebellum
and brainstem. The presence of anti-PrP positive
amyloid plaques and ATD pathology have also been
recorded.
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8
PARIETAL CLIN BG CLIN
1 009 0 1 1 1
2 007 1 0 0 1
3 020 1 1 1 0
4 024 0 1 1 0
5 091 1 0 1 0
6 043 1 1 1 0
7 047 0 0 1 1
8 057 1 1 0 1
9 067 0 1 1 0
10 070 1 1 1 1
11 251 0 1 1 0
12 086 0 1 1 1
13 089 1 1 1 1
14 090 1 1 1 0
15 097 0 1 1 1
16 105 0 1 1 0
17 135 1 1 1 1
18 109 0 1 1 1
19 117 0 0 1 0
20 120 0 0 >t 1 0
21 113 1 1 1 0
22 114 1 1 1 0
23 115 1 1 1 0
24 222 0 1 1 0
25 229 1 1 1 0
26 227 1 0 1 1
27 240 1 1 1 1
28 242 1 1 1 1
29 243 0 1 0 1
30 244 1 1 1 0
31 245 . 0 1 1 0
32 248 1 1 1 0
33 286 0 1 1 0
34 250
I
0 0 1 1
35 265 0 0 1 0
36 256 1 1 1 1
37 257 1 1 0 1
38 268 1 0 1 1
39 284 1 1 1 0
40 304 1 0 0 0
41 310 1 0 1 1
42 276 1 1 1 1
43 278 1 0 1 0




46 283 0 1 1 0
47 116 1 1 1 0
48 118 1 1 1 1
49 125 1 1 1 0
50 132 0 • 1 1 0
51 136 1 1 1 0
52 143 1 . 1 1 0
53 146 0 ' 0 1 0
54 147 1 1 1 1
55 148 : 1 ? 1 1 1
56 149
"
1 - 1 1 0
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OCCIPITA CLIN CEREBELL
1 009 0 1 1
2 007 1 0 0
3 020 1 0 1
4 024 1 0 1
5 091 1 0 1
6 043 1 0 1
7 047 1 1 1
8 057 0 0 1
9 067 1 0 1
10 070 1 1 1
11 251 0 1 1
12 086 0 1 1
13 089 1 1 1
14 090 1 0 1
15 097 1 1 1
16 105 1 0 1
17 135 1 0 1
18 109 1 0 1
19 117 0 0 1
20 120 1 0 / 1
21 113 1 1 1
22 114 1 1 1
23 115 1 1 1
24 222 1 1 1
25 229 1 0 1
26 227 1 1 1
27 240 0 1 1
28 242 0 1 0
29 243 0 1 1
30 244 1 0 1
31 245 - 1 1 1
32 248 1 1 1




35 265 1 1 1
36 256 1 0 1
37 257 1 0 0
38 268 1 1 1
39 284 1 1 1
40 304 1 0 1
41 310 1 1 1
42 276 1 0 1
43 278 1 1 1
44 277 1 1 1
45 288 1 1 1
46 283 1 1 1
47 116 1 0 1
48 118 1 0 1
49 125 1 1 1
50 132 1 1 1
51 136 1 0 1
52 143 1 1 1
53 146 0 1 1
54 147 1 0 1
55 148 , 1 0 1
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FRONTAL CLIN TEMPORAL CLIN
57 161 1 1 1 0
58 155 0 1 0 1
59 157 1 1 1 0
60 164 1 1 1 0
61 254 0 0 0 1
62 194 1 1 1 1
63 174 0 0 0 1
64 193 0 1 1 1
65 196 0 1 1 1
66 197 1 1 1 1
67 205 0 1 0 0
68 207 1 1 1 1
69 220 1 1 1 0
70 208 1 1 1 0
71 223 1 1 1 1
72 305 1 1 1 1
73 285 1 1 1 0
1
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PARIETAL CLIN BG CLIN
57 161 1 1 1 1
58 155 0 1 1 0
59 157 0 0 1 1
60 164 1 0 1 0
61 254 0 0 1 1
62 194 0 1 1 0
63 174 1 0 1 1
64 193 1 1 1 0
65 196 0 0 1 0
66 197 1 1 1 1
67 205 1 0 1 0
68 207 1 1 1 1
69 220 1 0 1 0
70 208 1 0 1 1
71 223 1 0 1 1
72 305 1 0 1 1
73 285 1 0 1 0
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OCCIPITA CLIN CEREBELL
57 161 0 0 0
58 155 1 0 1
59 157 1 1 1
60 164 1 1 1
61 254 1 1 1
62 194 0 0 1
63 174 1 1 1
64 193 1 0 1
65 196 1 1 1
66 197 1 1 1
67 205 0 0 0
68 207 1 0 0
69 220 1 1 1
70 208 1 0 1
71 223 1 0 1
72 305 0 0 1
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Legends for Appendices 6 and 7:
Following genetic counselling an information sheet
summarising the main points was given to the relatives, and
their consent was obtained for PRNP analysis. Relatives
were requested to indicate whether the results of genome
analysis should be made known to them.
Appendix 6
INFORMATION TO BE GIVEN TO RELATIVES OF CJD PATIENTS WHEN CONSENT IS
BEING OBTAINED FOR BLOOD TO BE TAKEN FOR GENETIC STUDIES
1. The cause of CJD in the great majority of patients is unknown.
2. A small proportion of cases are hereditary in nature due to a faulty gene.
3. In nearly all the hereditary cases, the family are already aware of other affected family
members. In these families about half the family members can be affected by CJD and
the disease may occur from generation to generation.
4. The chances of finding a faulty gene in a case of CJD without any other affected family
members is very small, probably less than 1 in 50.
5. We wish to take blood from cases of CJD in order to look for abnormalities in the gene
/
and we also store blood for future research.
6. In this way we hope to advance knowledge in CJD which may, in the future, lead to a
better understanding of the disease.
7. If you do not want to know the result of this test, we will not inform you, your family
doctor or the hospital doctor of the result.
8. If you''do want to know the result of the test, this will be done through the local genetic
counselling clinic even if the test is negative which is the most likely outcome.
i
9. The chances of finding an abnormality in the genetic test are very low and in the great
majority of cases there is no increased risk of developing this disease in family
members. It is particularly important to know that CJD is not infectious and there is no
risk from contact with patients during their illness.
10. Summary
* There is no risk of developing CJD by contact.
* Only a small proportion of cases are hereditary.
* The blood sample will help research
* The result of the genetic test will only be made available IF YOU WANT IT TO BE.
Appendix 7
National Creutzfeldt-Jakob Disease Surveillance Unit
Please reply to: Western General Hospital, Creiue Road, EDINBURGH EH4 2XU
Clinical Office:
(Department of Clinical Neurosciences)
Tel: 0131 332 2117
Fax: 0131 343 1404
Dr RG Will, Consultant Neurologist
Dr M Zeidler, Research Fellow
Miss JM Mackenzie, Study Co-ordinator
Neuropathology Laboratory:
(Department of Pathology)
Tel: 0131 537 19S0
Fax: 0131 537 1013
Dr JE Bell, Consultant Neuropathologist
Dr JW Ironside, Consultant Neuropathologist
Mrs L McCardle, Senior MLSO (Direct Line) 013 1 537 1981
CONSENT FORM FOR GENETIC ANALYSIS IN CJD
I consent to a blood sample being taken
from myself/my relative for the purposes of




The research on the blood sample will principally involve studies that will not have
any direct implications for individuals, although we hope that they will help us
understand the disorder better in future. However, in a few cases, Creutzfeldt-Jakob
disease may result from a change in a genetic factor that could give a risk to family
members. In view of this,
1. Would- you like to know any test result that might suggest a risk to other family
members?
YES/NO
2. It is possible that information from this research that does not appear to be
important now, might become so in the future. If this were to occur, would you
like to be informed?
YES/NO
Signed
Signed Research Registrar
